Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof

ABSTRACT

The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the secreted peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the secreted peptides, and methods of identifying modulators of the secreted peptides.

FIELD OF THE INVENTION

[0001] The present invention is in the field of secreted proteins that are related to the epidermal growth factor subfamily, recombinant DNA molecules, and protein production. The present invention specifically provides novel secreted peptides and proteins and nucleic acid molecules encoding such secreted peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

BACKGROUND OF THE INVENTION

[0002] Secreted Proteins

[0003] Many human proteins serve as pharmaceutically active compounds. Several classes of human proteins that serve as such active compounds include hormones, cytokines, cell growth factors, and cell differentiation factors. Most proteins that can be used as a pharmaceutically active compound fall within the family of secreted proteins. It is, therefore, important in developing new pharmaceutical compounds to identify secreted proteins that can be tested for activity in a variety of animal models. The present invention advances the state of the art by providing many novel human secreted proteins.

[0004] Secreted proteins are generally produced within cells at rough endoplasmic reticulum, are then exported to the golgi complex, and then move to secretory vesicles or granules, where they are secreted to the exterior of the cell via exocytosis.

[0005] Secreted proteins are particularly useful as diagnostic markers. Many secreted proteins are found, and can easily be measured, in serum. For example, a ‘signal sequence trap’ technique can often be utilized because many secreted proteins, such as certain secretory breast cancer proteins, contain a molecular signal sequence for cellular export. Additionally, antibodies against particular secreted serum proteins can serve as potential diagnostic agents, such as for diagnosing cancer.

[0006] Secreted proteins play a critical role in a wide array of important biological processes in humans and have numerous utilities; several illustrative examples are discussed herein. For example, fibroblast secreted proteins participate in extracellular matrix formation. Extracellular matrix affects growth factor action, cell adhesion, and cell growth. Structural and quantitative characteristics of fibroblast secreted proteins are modified during the course of cellular aging and such aging related modifications may lead to increased inhibition of cell adhesion, inhibited cell stimulation by growth factors, and inhibited cell proliferative ability (Eleftheriou et al., Mutat Res 1991 March-November;256(2-6):127-38).

[0007] The secreted form of amyloid beta/A4 protein precursor (APP) functions as a growth and/or differentiation factor. The secreted form of APP can stimulate neurite extension of cultured neuroblastoma cells, presumably through binding to a cell surface receptor and thereby triggering intracellular transduction mechanisms. (Roch et al., Ann N Y Acad Sci Sep. 24, 1993 ;695:149-57). Secreted APPs modulate neuronal excitability, counteract effects of glutamate on growth cone behaviors, and increase synaptic complexity. The prominent effects of secreted APPs on synaptogenesis and neuronal survival suggest that secreted APPs play a major role in the process of natural cell death and, futhermore, may play a role in the development of a wide variety of neurological disorders, such as stroke, epilepsy, and Alzheimer's disease (Mattson et al., Perspect Dev Neurobiol 1998; 5(4):337-52).

[0008] Breast cancer cells secrete a 52K estrogen-regulated protein (see Rochefort et al., Ann N Y Acad Sci 1986;464:190-201). This secreted protein is therefore useful in breast cancer diagnosis.

[0009] Two secreted proteins released by platelets, platelet factor 4 (PF4) and beta-thromboglobulin (betaTG), are accurate indicators of platelet involvement in hemostasis and thrombosis and assays that measure these secreted proteins are useful for studying the pathogenesis and course of thromboembolic disorders (Kaplan, Adv Exp Med Biol 1978; 102:105-19).

[0010] Vascular endothelial growth factor (VEGF) is another example of a naturally secreted protein. VEGF binds to cell-surface heparan sulfates, is generated by hypoxic endothelial cells, reduces apoptosis, and binds to high-affinity receptors that are up-regulated by hypoxia (Asahara et al., Semin Interv Cardiol Sep. 1, 1996 ;(3):225-32).

[0011] Many critical components of the immune system are secreted proteins, such as antibodies, and many important functions of the immune system are dependent upon the action of secreted proteins. For example, Saxon et al., Biochem Soc Trans May 25, 1997 ;(2):383-7, discusses secreted IgE proteins.

[0012] For a further review of secreted proteins, see Nilsen-Hamilton et al., Cell Biol Int Rep Sep. 6, 1982 ;(9):815-36.

[0013] Epidermal growth factors

[0014] The novel human protein, and encoding gene, provided by the present invention is related to the epidermal growth factor (EGF) superfamily, including proteins containing EGF or EGF-like domains and other EGF-related proteins such as those containing a CUB (Cls-like) domain such as Scube1 (see Grimmond et al., Genomics 70 (1), 74-81 (2000)).

[0015] EGF proteins play important roles as signaling molecules, growth factors, and as part of the extracellular matrix. EGF proteins are also known to be important in vertebrate development (Grimmond et al., Genomics 70 (1), 74-81 (2000)).

[0016] Scubel has been found to be highly expressed in developing gonads, nervous system, somites, surface ectoderm, and limb buds of the mouse (Grimmond et al., Genomics 70 (1), 74-81 (2000)).

[0017] The protein of the present invention is expressed in pancreas adenocarcinoma (as well as in the brain), and therefore is a potential target for treating pancreatic cancer.

[0018] Secreted proteins, particularly members of the epidermal growth factor protein subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of pharmaceutical development to identify and characterize previously unknown members of this subfamily of secreted proteins. The present invention advances the state of the art by providing previously unidentified human secreted proteins that have homology to members of the epidermal growth factor protein subfamily.

SUMMARY OF THE INVENTION

[0019] The present invention is based in part on the identification of amino acid sequences of human secreted peptides and proteins that are related to the epidermal growth factor protein subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate secreted protein activity in cells and tissues that express the secreted protein. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma.

DESCRIPTION OF THE FIGURE SHEETS

[0020]FIG. 1 provides the nucleotide sequence of a cDNA molecule that encodes the secreted protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma.

[0021]FIG. 2 provides the predicted amino acid sequence of the secreted protein of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

[0022]FIG. 3 provides genomic sequences that span the gene encoding the secreted protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in FIG. 3, SNPs were identified at 13 nucleotide positions.

DETAILED DESCRIPTION OF THE INVENTION

[0023] General Description

[0024] The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a secreted protein or part of a secreted protein and are related to the epidermal growth factor protein subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human secreted peptides and proteins that are related to the epidermal growth factor protein subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these secreted peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the secreted protein of the present invention.

[0025] In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known secreted proteins of the epidermal growth factor protein subfamily and the expression pattern observed. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known epidermal growth factor family or subfamily of secreted proteins.

[0026] Specific Embodiments

[0027] Peptide Molecules

[0028] The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the secreted protein family of proteins and are related to the epidermal growth factor protein subfamily (protein sequences are provided in FIG. 2, transcript/cDNA sequences are provided in FIG. 1 and genomic sequences are provided in FIG. 3). The peptide sequences provided in FIG. 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the information in FIG. 3, will be referred herein as the secreted peptides of the present invention, secreted peptides, or peptides/proteins of the present invention.

[0029] The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the secreted peptides disclosed in the FIG. 2, (encoded by the nucleic acid molecule shown in FIG. 1, transcript/cDNA or FIG. 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

[0030] As used herein, a peptide is said to be “isolated” or “purified” when it is substantially free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

[0031] In some uses, “substantially free of cellular material” includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein preparation.

[0032] The language “substantially free of chemical precursors or other chemicals” includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of the secreted peptide having less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

[0033] The isolated secreted peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using known protein synthesis methods. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. For example, a nucleic acid molecule encoding the secreted peptide is cloned into an expression vector, the expression vector introduced into a host cell and the protein expressed in the host cell. The protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Many of these techniques are described in detail below.

[0034] Accordingly, the present invention provides proteins that consist of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). The amino acid sequence of such a protein is provided in FIG. 2. A protein consists of an amino acid sequence when the amino acid sequence is the final amino acid sequence of the protein.

[0035] The present invention further provides proteins that consist essentially of the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein consists essentially of an amino acid sequence when such an amino acid sequence is present with only a few additional amino acid residues, for example from about 1 to about 100 or so additional residues, typically from 1 to about 20 additional residues in the final protein.

[0036] The present invention further provides proteins that comprise the amino acid sequences provided in FIG. 2 (SEQ ID NO:2), for example, proteins encoded by the transcript/cDNA nucleic acid sequences shown in FIG. 1 (SEQ ID NO:1) and the genomic sequences provided in FIG. 3 (SEQ ID NO:3). A protein comprises an amino acid sequence when the amino acid sequence is at least part of the final amino acid sequence of the protein. In such a fashion, the protein can be only the peptide or have additional amino acid molecules, such as amino acid residues (contiguous encoded sequence) that are naturally associated with it or heterologous amino acid residues/peptide sequences. Such a protein can have a few additional amino acid residues or can comprise several hundred or more additional amino acids. The preferred classes of proteins that are comprised of the secreted peptides of the present invention are the naturally occurring mature proteins. A brief description of how various types of these proteins can be made/isolated is provided below.

[0037] The secreted peptides of the present invention can be attached to heterologous sequences to form chimeric or fusion proteins. Such chimeric and fusion proteins comprise a secreted peptide operatively linked to a heterologous protein having an amino acid sequence not substantially homologous to the secreted peptide. “Operatively linked” indicates that the secreted peptide and the heterologous protein are fused in-frame. The heterologous protein can be fused to the N-terminus or C-terminus of the secreted peptide.

[0038] In some uses, the fusion protein does not affect the activity of the secreted peptide per se. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant secreted peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

[0039] A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see Ausubel et al., Current Protocols in Molecular Biology, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A secreted peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the secreted peptide.

[0040] As mentioned above, the present invention also provides and enables obvious variants of the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants exclude any amino acid sequences disclosed prior to the invention.

[0041] Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the secreted peptides of the present invention. The degree of homology/identity present will be based primarily on whether the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

[0042] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid “identity” is equivalent to amino acid or nucleic acid “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0043] The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48):444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (Devereux, J., et al., Nucleic Acids Res. 12(1):387 (1984)) (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

[0044] The nucleic acid and protein sequences of the present invention can further be used as a “query sequence” to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (J. Mol. Biol. 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score=100, wordlength=12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score=50, wordlength=3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al. (Nucleic Acids Res. 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

[0045] Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the secreted peptides of the present invention as well as being encoded by the same genetic locus as the secreted peptide provided herein. As indicated in FIG. 3, the gene encoding the secreted protein of the present invention was mapped to chromosome 22.

[0046] Allelic variants of a secreted peptide can readily be identified as being a human protein having a high degree (significant) of sequence homology/identity to at least a portion of the secreted peptide as well as being encoded by the same genetic locus as the secreted peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in FIG. 3, such as the genomic sequence mapped to the reference human. As indicated in FIG. 3, the gene encoding the secreted protein of the present invention was mapped to chromosome 22. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a secreted peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

[0047]FIG. 3 provides information on SNPs that have been found at 13 nucleotide positions in the gene encoding the secreted proteins of the present invention.

[0048] Paralogs of a secreted peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the secreted peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will hybridize to a secreted peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

[0049] Orthologs of a secreted peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the secreted peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a secreted peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

[0050] Non-naturally occurring variants of the secreted peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the secreted peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a secreted peptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which amino acid changes are likely to be phenotypically silent are found in Bowie et al., Science 247:1306-1310 (1990).

[0051] Variant secreted peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to phosphorylate substrate, ability to mediate signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. FIG. 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect function to some degree.

[0052] Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

[0053] Amino acids that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham et al., Science 244:1081-1085 (1989)), particularly using the results provided in FIG. 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as secreted protein activity or in assays such as an in vitro proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith et al., J Mol. Biol 224:899-904 (1992); de Vos et al. Science 255:306-312 (1992)).

[0054] The present invention further provides fragments of the secreted peptides, in addition to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in FIG. 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

[0055] As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous amino acid residues from a secreted peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the secreted peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the secreted peptide, e.g., active site or a substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The results of one such analysis are provided in FIG. 2.

[0056] Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art. Common modifications that occur naturally in secreted peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in FIG. 2).

[0057] Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

[0058] Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as Proteins—Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., Posttranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter et al (Meth. EnzymoL 182: 626-646 (1990)) and Rattan et al. (Ann. N.Y. Acad. Sci. 663:48-62 (1992)).

[0059] Accordingly, the secreted peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature secreted peptide is fused with another compound, such as a compound to increase the half-life of the secreted peptide (for example, polyethylene glycol), or in which the additional amino acids are fused to the mature secreted peptide, such as a leader or secretory sequence or a sequence for purification of the mature secreted peptide or a pro-protein sequence.

[0060] Protein/Peptide Uses

[0061] The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a secreted protein-effector protein interaction or secreted protein-ligand interaction), the protein can be used to identify the binding partner/ligand so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

[0062] Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

[0063] The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, secreted proteins isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the secreted protein. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis). A large percentage of pharmaceutical agents are being developed that modulate the activity of secreted proteins, particularly members of the epidermal growth factor subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention, particularly in combination with the expression information provided in FIG. 1. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. Such uses can readily be determined using the information provided herein, that which is known in the art, and routine experimentation.

[0064] The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to secreted proteins that are related to members of the epidermal growth factor subfamily. Such assays involve any of the known secreted protein functions or activities or properties useful for diagnosis and treatment of secreted protein-related conditions that are specific for the subfamily of secreted proteins that the one of the present invention belongs to, particularly in cells and tissues that express the secreted protein. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis).

[0065] The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the secreted protein, as a biopsy or expanded in cell culture. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the secreted protein.

[0066] The polypeptides can be used to identify compounds that modulate secreted protein activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the secreted protein. Both the secreted proteins of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds for the ability to bind to the secreted protein. These compounds can be further screened against a fimctional secreted protein to determine the effect of the compound on the secreted protein activity. Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate (antagonist) the secreted protein to a desired degree.

[0067] Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the secreted protein and a molecule that normally interacts with the secreted protein, e.g. a substrate or a component of the signal pathway that the secreted protein normally interacts (for example, another secreted protein). Such assays typically include the steps of combining the secreted protein with a candidate compound under conditions that allow the secreted protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the secreted protein and the target.

[0068] Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam et al., Nature 354:82-84 (1991); Houghten et al., Nature 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids; 2) phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang et al., Cell 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab′)₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural product libraries).

[0069] One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant secreted proteins or appropriate fragments containing mutations that affect secreted protein function and thus compete for substrate. Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a fragment that binds substrate but does not allow release, is encompassed by the invention.

[0070] Any of the biological or biochemical functions mediated by the secreted protein can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly FIG. 2. Specifically, a biological function of a cell or tissues that expresses the secreted protein can be assayed. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis).

[0071] Binding and/or activating compounds can also be screened by using chimeric secreted proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate then that which is recognized by the native secreted protein. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the secreted protein is derived.

[0072] The proteins of the present invention are also useful in competition binding assays in methods designed to discover compounds that interact with the secreted protein (e.g. binding partners and/or ligands). Thus, a compound is exposed to a secreted protein polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble secreted protein polypeptide is also added to the mixture. If the test compound interacts with the soluble secreted protein polypeptide, it decreases the amount of complex formed or activity from the secreted protein target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the secreted protein. Thus, the soluble polypeptide that competes with the target secreted protein region is designed to contain peptide sequences corresponding to the region of interest.

[0073] To perform cell free drug screening assays, it is sometimes desirable to immobilize either the secreted protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

[0074] Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., ³⁵S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of secreted protein-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein trapped in the wells by antibody conjugation. Preparations of a secreted protein-binding protein and a candidate compound are incubated in the secreted protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the secreted protein target molecule, or which are reactive with secreted protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

[0075] Agents that modulate one of the secreted proteins of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

[0076] Modulators of secreted protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the secreted protein pathway, by treating cells or tissues that express the secreted protein. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. These methods of treatment include the steps of administering a modulator of secreted protein activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

[0077] In yet another aspect of the invention, the secreted proteins can be used as “bait proteins” in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos et al. (1993) Cell 72:223-232; Madura et al. (1993) J. Biol. Chem. 268:12046-12054; Bartel et al. (1993) Biotechniques 14:920-924; Iwabuchi et al. (1993) Oncogene 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the secreted protein and are involved in secreted protein activity.

[0078] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for a secreted protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a secreted protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the secreted protein.

[0079] This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a secreted protein-modulating agent, an antisense secreted protein nucleic acid molecule, a secreted protein-specific antibody, or a secreted protein-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

[0080] The secreted proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. The method involves contacting a biological sample with a compound capable of interacting with the secreted protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

[0081] One agent for detecting a protein in a sample is an antibody capable of selectively binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

[0082] The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered secreted protein activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

[0083] In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected in vivo in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

[0084] The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (Clin. Exp. Pharmacol. Physiol. 23(10-11):983-985 (1996)), and Linder, M. W. (Clin. Chem. 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound. Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharnacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects, show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the secreted protein in which one or more of the secreted protein functions in one population is different from those in another population. The peptides thus allow a target to ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and secreted protein activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to genotyping, specific polymorphic peptides could be identified.

[0085] The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. Accordingly, methods for treatment include the use of the secreted protein or fragments.

[0086] Antibodies

[0087] The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

[0088] As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or F(ab′)₂, and Fv fragments.

[0089] Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, Antibodies, Cold Spring Harbor Press, (1989).

[0090] In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in FIG. 2, and domain of sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

[0091] Antibodies are preferably prepared from regions or discrete fragments of the secreted proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity and/or secreted protein/binding partner interaction. FIG. 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

[0092] An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see FIG. 2).

[0093] Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidinibiotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

[0094] Antibody Uses

[0095] The antibodies can be used to isolate one of the proteins of the present invention by standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal development. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis). Further, such antibodies can be used to detect protein in situ, in vitro, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

[0096] Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

[0097] The antibodies can also be used to assess normal and aberrant subcellular localization of cells in the various tissues in an organism. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

[0098] Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

[0099] The antibodies are also useful for tissue typing. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

[0100] The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the secreted peptide to a binding partner such as a substrate. These uses can also be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See FIG. 2 for structural information relating to the proteins of the present invention.

[0101] The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nuleic acid arrays and similar methods have been developed for antibody arrays.

[0102] Nucleic Acid Molecules

[0103] The present invention further provides isolated nucleic acid molecules that encode a secreted peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the secreted peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof

[0104] As used herein, an “isolated” nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′ and 3′ ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

[0105] Moreover, an “isolated” nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

[0106] For example, recombinant DNA molecules contained in a vector are considered isolated. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

[0107] Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.

[0108] The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.

[0109] The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in FIG. 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in FIG. 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule. In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

[0110] In FIGS. 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (FIG. 3) and cDNA/transcript sequences (FIG. 1), the nucleic acid molecules in the Figures will contain genomic intronic sequences, 5′ and 3′ non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in FIGS. 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

[0111] The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case in situ, the additional amino acids may be processed away from the mature protein by cellular enzymes.

[0112] As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the secreted peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5′ and 3′ sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

[0113] Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

[0114] The invention further provides nucleic acid molecules that encode fragments of the peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the secreted proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions.

[0115] Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

[0116] The present invention further provides non-coding fragments of the nucleic acid molecules provided in FIGS. 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be identified as being 5′ to the ATG start site in the genomic sequence provided in FIG. 3.

[0117] A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers. Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

[0118] A probe/primer typically comprises substantially a purified oligonucleotide or oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

[0119] Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by genetic locus of the encoding gene. As indicated in FIG. 3, the gene encoding the secreted protein of the present invention was mapped to chromosome 22.

[0120]FIG. 3 provides information on SNPs that have been found at 13 nucleotide positions in the gene encoding the secreted proteins of the present invention.

[0121] As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent hybridization conditions are hybridization in 6×sodium chloride/sodium citrate (SSC) at about 45 C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

[0122] Nucleic Acid Molecule Uses

[0123] The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in FIG. 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the same or related peptides shown in FIG. 2. As illustrated in FIG. 3, SNPs were identified at 13 nucleotide positions.

[0124] The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5′ noncoding regions, the coding region, and 3′ noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

[0125] The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

[0126] The nucleic acid molecules are also useful for constructing recombinant vectors. Such vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter in situ expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically introduced mutations.

[0127] The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

[0128] The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of in situ hybridization methods. As indicated in FIG. 3, the gene encoding the secreted protein of the present invention was mapped to chromosome 22.

[0129] The nucleic acid molecules are also useful in making vectors containing the gene regulatory regions of the nucleic acid molecules of the present invention.

[0130] The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

[0131] The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

[0132] The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

[0133] The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

[0134] The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis). Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in secreted protein expression relative to normal results.

[0135] In vitro techniques for detection of mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detecting DNA include Southern hybridizations and in situ hybridization.

[0136] Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a secreted protein, such as by measuring a level of a secreted protein-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a secreted protein gene has been mutated. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis).

[0137] Nucleic acid expression assays are useful for drug screening to identify compounds that modulate secreted protein nucleic acid expression.

[0138] The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the secreted protein gene, particularly biological and pathological processes that are mediated by the secreted protein in cells and tissues that express it. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma. The method typically includes assaying the ability of the compound to modulate the expression of the secreted protein nucleic acid and thus identifying a compound that can be used to treat a disorder characterized by undesired secreted protein nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the secreted protein nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

[0139] Thus, modulators of secreted protein gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of secreted protein mRNA in the presence of the candidate compound is compared to the level of expression of secreted protein mRNA in the absence of the candidate compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

[0140] The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate secreted protein nucleic acid expression in cells and tissues that express the secreted protein. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis). Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

[0141] Alternatively, a modulator for secreted protein nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the secreted protein nucleic acid expression in the cells and tissues that express the protein. Experimental data as provided in FIG. 1 indicates expression in the brain and pancreas adenocarcinoma.

[0142] The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the secreted protein gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be commensurately decreased.

[0143] The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in secreted protein nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in secreted protein genes and gene expression products such as mRNA. The nucleic acid molecules can be used as hybridization probes to detect naturally occurring genetic mutations in the secreted protein gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as amplification. Detection of a mutated form of the secreted protein gene associated with a dysfinction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a secreted protein.

[0144] Individuals carrying mutations in the secreted protein gene can be detected at the nucleic acid level by a variety of techniques. FIG. 3 provides information on SNPs that have been found at 13 nucleotide positions in the gene encoding the secreted proteins of the present invention. As indicated in FIG. 3, the gene encoding the secreted protein of the present invention was mapped to chromosome 22. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran et al., Science 241:1077-1080 (1988); and Nakazawa et al., PNAS 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya et al, Nucleic Acids Res. 23:675-682 (1995)). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

[0145] Alternatively, mutations in a secreted protein gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis.

[0146] Further, sequence-specific ribozymes (U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

[0147] Sequence changes at specific locations can also be assessed by nuclease protection assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant secreted protein gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C. W., (1995) Biotechniques 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen et al., Adv. Chromatogr. 36:127-162 (1996); and Griffin et al, Appl. Biochem. Biotechnol. 38:147-159 (1993)).

[0148] Other methods for detecting mutations in the gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers et al., Science 230:1242 (1985)); Cotton et al., PNAS 85:4397 (1988); Saleeba et al., Meth. Enzymol. 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita et al., PNAS 86:2766 (1989); Cotton et al, Mutat. Res. 285:125-144 (1993); and Hayashi et al., Genet. Anal. Tech. Appl. 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (Myers et al, Nature 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

[0149] The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the secreted protein gene in an individual in order to select an appropriate compound or dosage regimen for treatment. FIG. 3 provides information on SNPs that have been found at 13 nucleotide positions in the gene encoding the secreted proteins of the present invention.

[0150] Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

[0151] The nucleic acid molecules are thus useful as antisense constructs to control secreted protein gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of secreted protein. An antisense RNA or DNA nucleic acid molecule would hybridize to the mRNA and thus block translation of mRNA into secreted protein.

[0152] Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of secreted protein nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired secreted protein nucleic acid expression. This technique involves cleavage by means of ribozyrnes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the secreted protein, such as substrate binding.

[0153] The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in secreted protein gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered ex vivo and returned to the patient, are introduced into an individual where the cells produce the desired secreted protein to treat the individual.

[0154] The invention also encompasses kits for detecting the presence of a secreted protein nucleic acid in a biological sample. Experimental data as provided in FIG. 1 indicates that secreted proteins of the present invention are expressed in the brain (as indicated by the tissue source of the cDNA clone) and pancreas adenocarcinoma (as indicated by virtual northern blot analysis). For example, the kit can comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting secreted protein nucleic acid in a biological sample; means for determining the amount of secreted protein nucleic acid in the sample; and means for comparing the amount of secreted protein nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect secreted protein mRNA or DNA.

[0155] Nucleic Acid Arrays

[0156] The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in FIGS. 1 and 3 (SEQ ID NOS:1 and 3).

[0157] As used herein “Arrays” or “Microarrays” refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in U.S. Pat. No. 5,837,832, Chee et al., PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93:10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown et al., U.S. Pat. No. 5,807,522.

[0158] The microarray or detection kit is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or detection kit may contain oligonucleotides that cover the known 5′, or 3′, sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

[0159] In order to produce oligonucleotides to a known sequence for a microarray or detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5′ or at the 3′ end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The “pairs” will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

[0160] In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a “gridded” array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

[0161] In order to conduct sample analysis using a microarray or detection kit, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

[0162] Using such arrays, the present invention provides methods to identify the expression of the secreted proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the present invention and or alleles of the secreted protein gene of the present invention. FIG. 3 provides information on SNPs that have been found at 13 nucleotide positions in the gene encoding the secreted proteins of the present invention.

[0163] Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, An Introduction to Radioimmunoassay and Related Techniques, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. et al., Techniques in Immunocytochemistry, Academic Press, Orlando, Fla. Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

[0164] The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

[0165] In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

[0166] Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

[0167] In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified secreted protein gene of the present invention can be routinely identified using the sequence information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

[0168] Vectors/host cells

[0169] The invention also provides vectors containing the nucleic acid molecules described herein. The term “vector” refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

[0170] A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid molecules when the host cell replicates.

[0171] The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

[0172] Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

[0173] The regulatory sequence to which the nucleic acid molecules described herein can be operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ, the lac, TRP, and TAC promoters from E. coli, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

[0174] In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

[0175] In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in expression vectors. Such regulatory sequences are described, for example, in Sambrook et al, Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

[0176] A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., Molecular Cloning: A Laboratory Manual. 2nd. ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1989).

[0177] The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

[0178] The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

[0179] The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells include, but are not limited to, E. coli, Streptomyces, and Salmonella typhimurium. Eukaryotic cells include, but are not limited to, yeast, insect cells such as Drosophila, animal cells such as COS and CHO cells, and plant cells.

[0180] As described herein, it may be desirable to express the peptide as a fusion protein. Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety. Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith et al., Gene 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion E. coli expression vectors include pTrc (Amann et al., Gene 69:301-315 (1988)) and pET 11 d (Studier et al., Gene Expression Technology: Methods in Enzymology 185:60-89 (1990)).

[0181] Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example E. coli. (Wada et al., Nucleic Acids Res. 20:2111-2118 (1992)).

[0182] The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., S. cerevisiae include pYepSec1 (Baldari, et al., EMBO J. 6:229-234 (1987)), pMFa (Kurjan et al., Cell 30:933-943(1982)), pJRY88 (Schultz et al, Gene 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, Calif.).

[0183] The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith et al., Mol. Cell Biol. 3:2156-2165 (1983)) and the pVL series (Lucklow et al., Virology 170:31-39 (1989)).

[0184] In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian expression vectors include pCDM8 (Seed, B. Nature 329:840(1987)) and pMT2PC (Kaufman et al., EMBO J. 6:187-195 (1987)).

[0185] The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. 2nd, ed, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

[0186] The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

[0187] The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

[0188] The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).

[0189] Host cells can contain more than one vector. Thus, different nucleotide sequences can be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

[0190] In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

[0191] Vectors generally include selectable markers that enable the selection of the subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

[0192] While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell-free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

[0193] Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as kinases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

[0194] Where the peptide is not secreted into the medium, which is typically the case with kinases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance liquid chromatography.

[0195] It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

[0196] Uses of vectors and host cells

[0197] The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a secreted protein or peptide that can be further purified to produce desired amounts of secreted protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

[0198] Host cells are also useful for conducting cell-based assays involving the secreted protein or secreted protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native secreted protein is useful for assaying compounds that stimulate or inhibit secreted protein function.

[0199] Host cells are also useful for identifying secreted protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant secreted protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native secreted protein.

[0200] Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a secreted protein and identifying and evaluating modulators of secreted protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

[0201] A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the secreted protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

[0202] Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the secreted protein to particular cells.

[0203] Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder et al, U.S. Pat. No. 4,873,191 by Wagner et al. and in Hogan, B., Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

[0204] In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso et al. PNAS 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of S. cerevisiae (O'Gorman et al. Science 251:1351-1355 (1991). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein is required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

[0205] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. et al. Nature 385:810-813 (1997) and PCT International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀, phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

[0206] Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an in vivo context. Accordingly, the various physiological factors that are present in vivo and that could effect substrate binding, secreted protein activation, and signal transduction, may not be evident from in vitro cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay in vivo secreted protein function, including substrate interaction, the effect of specific mutant secreted proteins on secreted protein function and substrate interaction, and the effect of chimeric secreted proteins. It is also possible to assess the effect of null mutations, that is, mutations that substantially or completely eliminate one or more secreted protein functions.

[0207] All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

1 5 1 1210 DNA Human 1 cggtggcgga gcggcgagca gcgagcagcg cctgcgggag cggccggtcg gtcgggtccc 60 cgcgccccgc acgcccgcac gcccagcggg gcccgcattg agcatgggcg cggcggccgt 120 gcgctggcac ttgtgcgtgc tgctggccct gggcacacgc gggcggctgg ccgggggcag 180 cgggctccca gggtcagtcg acgtggatga gtgctcagag ggcacagatg actgccacat 240 cgatgccatc tgtcagaaca cgcccaagtc ctacaaatgc ctctgcaagc caggctacaa 300 gggggaaggc aagcagtgtg aagacggagt tttgctcttg ttgcccaggc tggagtgcaa 360 cggcgcgatc tcggctcatc gcaacctccg cctccggagt ccaagcgatt ttcctgcttc 420 agcctcccga gtagctggga ttataggcat gcgccaccac gcctggctag gagcatgaag 480 tactttttta aaatattcat ctcacacacc ccaaggatgt ggctccaaat gcgggaatag 540 agcctgcact tgaatgcaac cactggctgg gggcctgaag acaaggtcct cagcgatcct 600 gagcctcagc ctcttctgtg tgacagcagc tcttaccctg gcctcacaca cacagctgcc 660 tcactccaat ctctgccttc atcatcccac ggctgccttc tctccgcgtg tctgtgtgtc 720 ttcacatggt attcttctcc ctgtatgtct gtgtccaatt tccctcttct taggacagca 780 gcattgtatt aaggcccacc ctaatctagt atgacctcat ctgaacttga ttacatctgc 840 aaagacccta cttccaagtc agatcacatt ctctggtcct gggggttggg acctcaacat 900 atctttttgc ggggacacaa tttaatccac aacagccctt taagaataaa catccataga 960 gctgtgctct gtcccctcca ttgctttacc atctccctgc tccacctgcc tgtttctcgt 1020 tctctggctg tcagtcctga aaaagtggtc tgagcctgat gagtgtcttg gaggtctgtg 1080 gtgcctcttc caggggcggc gactcctgga tatgttttta taataataaa tccacttgct 1140 ttggcaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200 aaaaaaaaaa 1210 2 124 PRT Human 2 Met Gly Ala Ala Ala Val Arg Trp His Leu Cys Val Leu Leu Ala Leu 1 5 10 15 Gly Thr Arg Gly Arg Leu Ala Gly Gly Ser Gly Leu Pro Gly Ser Val 20 25 30 Asp Val Asp Glu Cys Ser Glu Gly Thr Asp Asp Cys His Ile Asp Ala 35 40 45 Ile Cys Gln Asn Thr Pro Lys Ser Tyr Lys Cys Leu Cys Lys Pro Gly 50 55 60 Tyr Lys Gly Glu Gly Lys Gln Cys Glu Asp Gly Val Leu Leu Leu Leu 65 70 75 80 Pro Arg Leu Glu Cys Asn Gly Ala Ile Ser Ala His Arg Asn Leu Arg 85 90 95 Leu Arg Ser Pro Ser Asp Phe Pro Ala Ser Ala Ser Arg Val Ala Gly 100 105 110 Ile Ile Gly Met Arg His His Ala Trp Leu Gly Ala 115 120 3 58985 DNA Human misc_feature (1)...(58985) n = A,T,C or G 3 gtctaggaga agacagaggt aaaacccaga gcgagccaag ctctgatgag gtaactccag 60 gggactgcgg aagcccagag gaagcctcac acccagctgg aggcaggggt cagggtatgg 120 gcagaagagg aggggtgggc cctgtgaaga agggaaacca agggtgctcc tggcagggga 180 aagggtgcag gctctggggt gtgaaaaata ggacagctgt ggggttccct ttgcagcagt 240 ttggtgaggc tagggaccgt tagaaagatg acagaacata aagctgagtc atcccttaca 300 tcccaaaggg gtaagagatg acttgtttgc aacacagaga gctcataggt catttggagg 360 tgacaggagc catagtgtgc tccctgccaa agtcactgtg caattcagca gccttcggcc 420 tccactatcc cagcttggca tccagaggtt ccaagccatc ccgtgctgga ggcctggcta 480 tgggttccca cctgccagcc caccgcagtg caaaacagac tcatccgttt ctgcacgcag 540 ccctccagca catcactgtc atgtgcatac agtgctctgc agttttcaag atgcttccag 600 aacattctct ggctcactta ttcagtcctc gccttcactc atggaccttg gcagattctc 660 tatttgttct tctcatccat taggcaaata tcctctttat gttctgtgtc tagcccaggt 720 cacctgtcct aagaggcctc cctgacggcg ccctggggca gaagtgacct cctctttctc 780 tgctccacag gccgcctcct ttccttcacc tgtgaggggc ttacaggtgt gtcttctctc 840 catttccctc ctcctctgct cgctgagtcc tccacataga caacagctgc ctagaaggaa 900 ccactttctc tctgcctgca caccttagag ggtgataatt caccagcaaa cttgacctga 960 gcaatcgctt gggggcaggc tggggactac aacttggtac aagggacagc tacctctggg 1020 ctgaggggtc acagagtaac ctgcctccat tcctgccttg atttgtgggg atggagcctg 1080 gaagaagctt ctcttgctgc catcaagctt gaggggcacc tggctagggc tgggcggggg 1140 ggtgcctaat gaccaggcac attagagggc attgtttcaa gtaggtcaga gccccctgga 1200 agaacctccc ccaccacctc acactgcttg ccctgttgcc caatgcacaa gataatatgt 1260 ggttctgagg gaactcccca ccccctgcag aaactcaaag ctacacaatt gacggggaca 1320 aaataaagcc tgtcaacagc atctcccaaa ttaaaccagc agccaggagc agccgtgcag 1380 accgaaatgt ctggagcaat ggggtggggg ctcagtggag acaacaggca gcgcttcctt 1440 cttctttggg catctctgga ccccccacac ccccgatccc catgtagggg accccttgcc 1500 tcggccacca ggcccgtgcc acaagctgat gtgaagtcag atggggtgtg agagctggct 1560 ggacacagat ttaaccttcc agggctgagg agctcgtcta cggtaggttg gatgagggcg 1620 tgaagaagca tgtgtgagcg tgtgtgtgct ggagggtgtg agggtgtgag gctgtgtctg 1680 agtgattgca cgtgagagca tgtgtctgca tgtgtgactg tgtgtgtgtg tgtgtgtgtg 1740 tgtgtgtgtg cgtgtgtgtg ttgggggcag gaaagggagc tggtgtggag gggctcaaac 1800 tggtgcaggc agagtggaca aaaaaagaga aaagagttgt ctttgagtcg ggcctggaga 1860 gcaggagaag aaaaaaggag ctcttattgg tggttgtcaa ggagatgggc cttggggttt 1920 gctgaacttt cgtcccttaa agcgtcctgc ctggaactga gaggggccat ttatttccag 1980 ccgcccgtcc ctcccaggcc cggtgggacc agacccgaag ccgaccctcg ccaggcgtca 2040 ggtgtagacc ccaggccagg ccagagcagt tcctgggtct tcggaccggg atgcccgccc 2100 tgcccctcct cctggccccg cccggtctgt cacaggggga ggcctcggcc tcgcattccg 2160 ggcagcgaac ttcgccggcc gaggttagcc ccgtgcgggg gcctcccgcg ggaccgaccg 2220 ccaagcggca ttgtccgtcc cgggcgcccg cccggttcca gacgcaggtc ctgcggccgc 2280 cccgtgacaa gcacactgac gggccactgt cctttgacga gtgctaaaaa gttcgtttgt 2340 tttgaacgtc aattttcaag tgatcttcac gaggtttccc ctcccggttc cttcgctgct 2400 gcctcgcccg cactcggtcc ccagtaggtg ctcaagaaac gtccagcaaa cggcagcgca 2460 ggcgagtctg ctctgcgcgc tggcgcgttt cactgcccac ggatggcggg cgacctcacg 2520 ggatccccgg ttcgcaggat ccccgccccc gaggctgcct ctgggccggg aggggttacc 2580 ccagaggggc gtccactctc gacggcgggg gccggggcgc cgcgggcagg ggagggcgca 2640 gcctccaagc agccccagcc tggcctagac cccgcgccta gcgagccggc cggccaggcc 2700 cacacccccc acctgccgcc cgccccaggg gaagggtccc cccgacgacg cccgagcccc 2760 cctcttcctc ggagggccgg aggccggcgc ccattggccg gccctgggcg acgccccgcc 2820 cctccgacgc cacgggccaa tgagcgcgcg ctgtcagctc atcagccggg ctggctgggc 2880 ggctcgggag cccgagcggt ggcggagcgg cgagcagcga gcagcgcctg cgggagcggc 2940 cggtcggtcg ggtccccgcg ccccgcacgc ccgcacgccc agcggggccc gcattgagca 3000 tgggcgcggc ggccgtgcgc tggcacttgt gcgtgctgct ggccctgggc acacgcgggc 3060 ggctggccgg gggcagcggg ctcccaggta agcccccgac cgaggtgggg ggcggcgggc 3120 gcggggggct cgggcggccg aggcgcggtc ccggagggct tcttccccgc ggatcccgag 3180 ctcgccccgc gcggccccgc gccccctgcc tctttgcaaa gtaacttcta gggccggccc 3240 ggggcgcccc ctccccgcag cccgggcggc cggggctcct gagtccggcg gggccgcacc 3300 aggggtgggt gggccggggc cccgggaggg gaagcgcgag cgcgggagcg aggaagaaag 3360 gcggcggttc ccggggaccc cgcgtgcgga cctgggcggg gcgggacccc gagcgcagag 3420 gggcgctcct cctgggagag ggggcgcggg gcggggcggg cggaggggga cacgccagga 3480 ggtggacggg gaaagggacg gaccgagaga ccgggacggg gcgggaggtg cgggacagac 3540 ggacagaaga gccggcgccg agggagcaga caaaaggaag cccggagaaa agacagatgc 3600 ggaagggtag agaggaggcc cgcaccgccc ggggaaggag gaggaggccg gtggatcagg 3660 gggaatcaag agggatggtc ccaccgatga taagggagag agagaggagg agacggggga 3720 cagatggacg ccgcagaaaa acggggttgg ggggggcggt gagagggaga ccgggaaaga 3780 gagagggaca gagatacctg gaaagccgca gacgagggac cgggaccgtc tgacaggacg 3840 gggaggaaag acagagggaa ggaaggcaga ggatccggag gacagacaca gggaggagag 3900 tccggacgcg ggacgtcggt ggagcagacc caggaagggg agggggagac ccggaggcca 3960 caggcccagg cccgtgggtt tcacggggga cccccccacc ctcccacccg gtcccctcct 4020 gctctctgac tgtcttcagg ggcttcccga aaagctggag tcacattctc ccctcctcgt 4080 catcagaggc gcttcctccg gtgctctgct tggaggggga ggcaggggga gggtcctgca 4140 cgtccttccc ggcttcctga ggtctggtat gggtggcgta gggtctattc ctggtggtcc 4200 cgcgtgcccc gagtgaggat gctgggcctg tgagactctt ccacagcaac acccctcctg 4260 gaagcccagc cctgctgccc catcatcccc cttgtgtctg tgggtgtctc tcccaagctt 4320 tggggtccct cacctctgag tgactgttcc tgggcgtgcc tatccccacc tgtgtccctc 4380 ctcgtgtctc tctgtatctg actctgtctc ctccacgacc ctctccgtgg aagccctgtg 4440 actgtgaaac cccagcagca tgtccccagc ataagcaaac cagagtcaaa gggagcagcc 4500 tgtgctagga gggctgggtc gccctgcagg ggagtctcca gcccagacag gagcgggagc 4560 atggcagaga accgatgggg acaagtggct tctccctctc tctcctcaaa ctcccatgtc 4620 ctctccccac actccacacc aaggacaccc aagtgtttaa aggtgtgttg ggagatagct 4680 ccacccaccc ctcatcaaca tccatccatt tccattccag tgaagacacc tgcctaggtg 4740 ggagattagg ggtgagggca caaggggctc ccacccctca ttcctacata ctggcccctg 4800 ggaagtggga agagccatat ctgtggccca ctgcccctgc tggtcctgtc tcataagtga 4860 ccccagtcct cccaaacaga agcctggaga tgggccctct ctggcctctg ggtccctgcc 4920 ttagaggcag tgccagtcct gcacagtgtc cctctgttgc cacttcccca gaaggccctc 4980 atggatgttc ctgctggccc agccatccag ttgccggctg ggccccctcc agttcctgcc 5040 tccttgtccc ctttccactc ttcccctggg cagctgtcta ggacaggccg cccacctgag 5100 cagatgggta gccccccccg gaaagcaatg ccacctgccg tgtgtgtgcg cacacgtgca 5160 tgcatgtgtg tgtgtgtgtg tgtgcagggg ggtcatgctg ttgtgtttct tgttgatgcc 5220 tctcttcctt caggggtggg caggagactt aggggctagg gcaaagaagg agaagccctg 5280 gggggcatgg atctcatagg ccccactggc agatttcgaa cccagatatt atccagggga 5340 gaaatttaga gtggacactc ttggggaccc agcaatctaa ggtgagacca gaggcatgaa 5400 gagatgggga cattccaagc ttacccctgg ggcactgccc tcatggcagc tgctgagagt 5460 tccttgcact gctgcactcc tgggtccttc tgtctgtctg tcatgtctac atttcatgca 5520 ttgctagcta gaagtcacat ggcacatagg aaagctcatt ctgtgtcaga gtccagtctc 5580 agccccagtg agctactgac ccataacaga tttcacctca ctgggcctca gtttcctcat 5640 ctataacctg aggaatcaac ctggattata ggtacagctc tgactgtgct gaactgtgcc 5700 cgacaagagg cacgtcccct ccctgcctga actctgtgtg tgtgtgtgtg tgtgtgtgtg 5760 tgtgtgtgtg tgtgtgtgtg tgtgtaaaag agacaaggag agaggcttgg ggtgtataga 5820 tggaatggat acacagaatc tattttgcac aatttgcccc aacagctgtt ccagactgaa 5880 ggtgtatatg tgttgggggc aggaggtaga gagtgtcggg agccctcaaa gcctagactg 5940 aacttgcatt tataagttgg gacatgaaaa ccaggttcac gtgtggattt ccgaggaggg 6000 aggaccatgt ggggagtcag aaccatggat gggctcaggt tagcccagtt gagggtgtgg 6060 ttctgccacc agacactttg gtgtgggggc gtggaagcca gatgatgaat cccgtgtttc 6120 cacaggctag gggcagggtg ggatcccacg ttcaggtgac ctgcaggagc ctcctggcat 6180 ggccttggtg tccccatctg gaacccaaag ggactagatt taaactcctc caaggaccct 6240 tctggctcta aattctagaa tgaggagagt ggggggannn nnnnnnnnnn nnnnnnnnnn 6300 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6360 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6420 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6480 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6540 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6600 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6660 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6720 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6780 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6840 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6900 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 6960 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 7020 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 7080 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 7140 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 7200 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 7260 nnnnnnnnnn nnnnttgtgg ggggtagaat gaggagagtg ggggagggtt ggagcaatgc 7320 ttgtgggggc atagagtgag gagagtgggg gagggctgga gtgatgcttg tggggggata 7380 gagtaaggag agtaggggat agagtgagga gagtagggga gggctggagt gatgcttgtt 7440 gggggagtag gacagacgga ggaggaggtt cttcctcact gtctccttaa gcctcagttt 7500 tctcatcttt ttagcagaac aatagctcaa tgggatggtt gcgacaataa ataaggccaa 7560 gcgtattgat agcattgtcc ctgccacaga gtagctgcgc caaagatgct accagttgcc 7620 acttgtcaca ccagattgtc ctgtgacagc tgttattgcc aatgagccca ccgatcaatg 7680 gacgggcaaa ggcaagagct ccccctgccc tacactatcg gccacctgcc ctggggccac 7740 accttacctc ttattccccc cacaccccta cccacagggt cagtcgacgt ggatgagtgc 7800 tcagagggca cagatgactg ccacatcgat gccatctgtc agaacacgcc caagtcctac 7860 aaatgcctct gcaagccagg ctacaagggg gaaggcaagc agtgtgaagg tgagtccagc 7920 ccggccctcc cgggcagacc ctgaggctgc cagggctgct gtaggtggcc gatgcctgcc 7980 ccattcatca ccagctgggg ctgagcctcc agcaccacca ttgtggttgc tgacagcaca 8040 ggcttctctc agcctcagga gggaggcagt gaacttttcg gaaatgccgg ctgcttccct 8100 ggaagggtgg agttagagtc atggggtgcc tgattctcaa ctgggcttga aactttttgt 8160 tctttttaag aaattggctg ggtgcggtgg ctcacgtctg taatcccagc actttgggag 8220 accgaggcag gcagattacc tgaggtcaag agtttgagac cagcctggcc aacatggcaa 8280 aaccccatct ctactgaaaa tacaacaaat acaaaaaaag ttagccgagc gtggtggtgc 8340 atgcctataa tctcagctac tcgtgaagct gaggcaggag aatcacttga acccaggagg 8400 cagaggttgc agtgagccga gatggcgcca ctgcactcca gcttgggcga cagagcaaga 8460 ctctgtctca aaaaaaaaga aaagaaagaa aaagaaatta agatgaagca ttgaatgagg 8520 tatttgtgca tctgtccttg actggctata tgggggtgga gtgcaaagac ctgggcttgc 8580 cccccgaccc ccagagtccc taacgtcaag ttcaaaacca ccctgtaggt ctctgtctca 8640 agttccagtg cttggacaga cactggtgga tttgtgccat ctgtctctcc agcctttctg 8700 ccctgcacct ggggtgctgg ttagccctcc tgctattaaa aactgcctcc ccagcaggct 8760 aaaagttaga gagaaaagag cagctctggc tgtgtttggt gccaggactc tgcaagccca 8820 ttggaacctt tggagctttt gtccatgaga gtctgcatgg ccgtcctcac cccatgggtc 8880 tggggcagga ctgggcatct gggggctgga aatagctctc tccgagacag acagacaccc 8940 ctggatggga tcactgatcc cagtcttccc tgtctgcacc catcgtataa atgaggaaag 9000 ctgaggctca gacaggagaa gcatcttttg caagattccc atgttcacag tgatatgaca 9060 aggactgaaa tccaggtctt gtaactccca ctcaacaact ctggcagcta gttttcttct 9120 ccctgggccc tgccagctga atttttccaa gtttgatatt tgtattagga aagtgacatg 9180 ggagcacagg atgggtccct gctctttctg tataaggcgt ttacagggct agagttttgt 9240 gggcgatgca gccactcctc cctgggatgc tggtggtgtt tatccttcac atttgttgag 9300 catttattta aggctgagtg ctgggcagat gacatcgccc tggatcatgc ctggttgggt 9360 aatattcctg gcacgctcag ggcccagaac ccaaagtggg gagctggcgc ctacccacag 9420 acctctggaa ggaggccagg ctggaggcac acagaggagg ccatgagtga gaagcctggt 9480 ggggcggctg gcccggctgc tggcagggcc agaggttagc tcgctggttc gagtggtaca 9540 tgtgaggctg gtgtgaccgc tttctgaccc tctactctgc cttccagacc cagtgtcccg 9600 gaaaggcggg gccatggttg acccccctat ctctgctggt ttaagccact gacctggcct 9660 cttccttccc aagcccagct cctccttagg ccctctcctg ctgtcccctg cccgggaggc 9720 cttacctgtt tccctaaaat ttttcggagt tcagctttaa ctccttactc tgcttgaccc 9780 ccgagttagg agtcagactt ttgtcccaag cccagctctg ctgctcactg gctctgtagg 9840 cttcatgttc tcacctgcta gaaaaggaaa ttgttttgtc ctgctgggta tgaagatgag 9900 acaagaggag gcttgtgaat gtgcttcggg aactgccagg ggtctcccta tctctccagc 9960 caaattcggg cctccaccct tcacatcctg aaacactgaa caacacctct gtcctggcac 10020 atgcatgcac acacagacac acacacacac acacagacat acacacagac acacatgcat 10080 gcacacacac ttggttgctc tatgtttgtg agccccagct cagattttcc gcctgcctgg 10140 agctccttac cttctttctg tatcctgtct aaatctgaag gctaatcatt ctttaggttt 10200 gcctcctcca ggaagccttc tctgatacct ccacttatat acacacactt acacgtgcac 10260 acacatgcat gctagactgc aatgggtacc taccctgctc ccagaggctt ctgggcttcc 10320 ctccatcatc acacttctga ctctaggtca taattacttg tcttggtccc ccacagaact 10380 gtgagctcat ttattgaggg cccaccataa gcttgctgta agggccacca taccgaagct 10440 gtcaaactca ggccatgccc ccaggagctc ccagtgagct cctcaattag aggttctttt 10500 acatttgtag ccgtgttccc agctcacggg gcagggcctg gcactagcgc gggtctgcag 10560 aaaacattta gtctgagttg gctctccttt gcccagacag gacttcacat tagatgagca 10620 acctgtaaga tatccacaga ggggagtgcg gagtgtgggg tctgtggaag ggctcgttct 10680 ggccctggtg tcatcttgac cctgtgcaat gagacagagg aaagcagaga caaggctggt 10740 ctcttcgagg ggagcctggg ttgcaaccca cctctcatgt gaacatctgg gtggtaactt 10800 gccctcactg agccttagtt tctcctttgg ttgtgcgggc caaaaatact ccccatcaca 10860 ggtcagcctg aagattgagt gaggcacagt atagtgcact gggggctggc atccaataca 10920 cagtaggcac tcattccgta gagtgtgctc catatacaga tggcaaagtc ttcaccatga 10980 tcctgtcatt atcatcatct gcattatcac catcatcatt atcatcatca tcaccatcat 11040 catcatcacc atcatcatta tcatcttcat caccatcatc atcaccacca tcatcaccat 11100 catcattatc atcaccacca acatcaccat caccatcatc accatcacca tcatcaccac 11160 catcatcatt atcatcatca ccatcatcat caccatcatc atcatcatca ccatcatcat 11220 caccatcacc atcaccatca tcatcaccat catcatcatc atcatcatca tcacctgttc 11280 tcactagctg tcaaagtagt ttcaggctca aatgagacta tgaatggtga agacctttga 11340 aaattgctca gttctgcata cctgggaggt gatagttatg gtgcaacata gtccttggtc 11400 tccagaagct tgtggtctgg tggggctgca tgagctggaa attcctgata acagacttag 11460 ggtagcatgg gtcatgaatc agtgtctgtt gagttgccat gttaacagta tgagaacaat 11520 tgttaggaac caaaaggagg acatcgtttg gttatgggct tcctaaaccc tcagtgagtg 11580 agtgttggca tggattctgg aggcctgtgt agaccctgtt cttttagcac tctggttttc 11640 tcatccctgg ggacctactt acagtcatca atttgaatca agtcagcctg ccagagtgct 11700 cacatatata cctcataccc ccaacacata aacacggaga accatcagat ccctgctggc 11760 ttctctggga ggactatgga gagacaactg ggggctctga aatctgaagg ggcaccatgt 11820 gcagcagtgg cctgagggag ctgggaaacc atccagatgt tcacatcctt ggtttacaga 11880 tggaaaaatg gaggcctgag ggggcagggt ctttcctggg tggggactag agcccaggtt 11940 tgacagacct gtttctccac actgtgtttc tgcaggtggt tattcctatc tgtggctttc 12000 tgttctgaga agagggtgtt aacagcctct attaaggtca gcttaggagt taaagcattg 12060 actttggtgc cagatggctt gggttcaaat cctgcccgtg tagcctgggc aagtcattta 12120 acctccattt gtttatctat aaaataggca taatgttagt acttatttca tacagatagt 12180 gtgagaatta aatgagttaa tgtatttaaa gcctttgaac atagcttggc acatatgatg 12240 ctgtatataa gcactagctg cccttactgt gatgatgatg acggtgctat tgatgatgag 12300 ggtgatgggg gtgatgataa tgttgatggc gatgataatg ttgatggtgg tgatgataat 12360 gttgatggtg gtgatgataa tgttgatggt ggtgatgata atgttgatgg tgctgttatg 12420 gtgctgttga tgagggtgat gatgatggtg atattgatga tgatggtgct gaagaagatg 12480 atgatgatgt atctgatcat catcatcgtc actatgttga tgtcaatgat cacagtgttg 12540 ttcaagatgt gaaagaacta aagctttgtc ttttccaaca attcctggga cctaaaatgg 12600 ttgggaaatg aggtattctg gttcatcgac tgttcatata aaccatatgc atatacttat 12660 atccccacag aggtgaacag tcaggtgtgt cattcacaga tggctgctta tcaagaacat 12720 acaataagaa acacttagga aagaagactt tcctttgttc aactaagcct acttcgggga 12780 tggcaaatat gccatcacct tctgccatag cagacattaa taatcaatta ccgcaccctc 12840 cagtcatttt tgcagtagat gaaacttgct ttccctccct gggttcctgc atctgcaggt 12900 cctgagctgg agtagggttc tgccaaggct ggggttggag tcttggaggc agtgagcccc 12960 ctgtcctgca gatctcactg actgtgctct ttgctgtgat aagaataaag gatggactct 13020 cagcagagca tgccccgagg acatggctgc cacattctcc ccagttcttc accaccatgt 13080 tgagtgtttg cttccagaca ccctgctaca tgttccacgt ccatgatctc atttaatcct 13140 ctcaagaacc ctaccagata gggactatgc cttccatttt tcaagtgagg aaactgaggc 13200 atggagaggt aaagtgactg gccaaaggtt acacagttga tagaggagag ctagaattta 13260 agccccaaac cggcagttcc gaaggtctct cctcttgacc gctgggtgat actgcctgct 13320 tttaactggc tgtcccatag ggactgtaag atttgtcttt accaactaat cagtgcccga 13380 aatgtacttt ctctatcatt ttcacaaccc gagcctggat tgtgggaagc ccgatgtgag 13440 gctgaccgag cctcttaccc acttcaccag gtcaccttga aacttctgct gcttgagaaa 13500 tccctgttag caaatccagc cctggaggcc acctgccccc cattctggga acagtttctc 13560 ttcccacctt caagggcaac ttgtcttatg gccagtggac atgtgtgatg atggcatagc 13620 ctccacatgt ggagacatgt tgcatctgtg tccaggagtg gcctggggcc ccctgcggtc 13680 agcctaatgc cggtagaggg cttgctgtag ccagacaggt gagtgcctca gacagccggg 13740 aaaggctctg agcagggctg gagataaagc actgttttct tgattgaatc tgaagtgcct 13800 tgaggcaaag tcctggctgt gtggagttgg aagaaacttc gaagggcgtt gaggcagtcc 13860 ccgtgagtga cagctgccac ccctctttgc agctcacccc aggtccatac acaccaccat 13920 tttagcccat gccacactgc acttaggttt tcccacgtct cctcctggaa tgtgagctcc 13980 tcaaagaccg gatctgggac ctgtcagctc ccatccctgg aagctaggga ctgggcctgg 14040 cacagggtgt ggaaggcatt tgctggatga cagggtcacc tcctccagga agccatctct 14100 ggtcccccag acaggggagt tatcagctgt gaacatcctc cctcagtgct cctgtcacac 14160 taggttgtga ggacccatgt aacttccctc agggctgggc ccagagctgg tgtcggtgga 14220 cagtgaatga cccttatcca tgctgggagg acccaggaag gcctccagaa cctcacagac 14280 tctgagcgtt ctacagatga ggaagcagag gcttgcacag agagagagct agtctgagga 14340 taactggtgt ggaccgatgg cagaattcgc ctggggaaac tgggtccaga gaggtctgtc 14400 tctagccagg cctcccagct gagagggagc agggcctggg tttcgtcccc caccagccaa 14460 ggggtcccag catcaggcca ggcccccatc agcccatggg aaagcattag gggaggctcc 14520 tgcactatgg agggatcgag ggagctgtac agcccctctg cttctacacg gactcgctcc 14580 cttgctgctg ctggctggtc tgagacagga cctgggaatg ggaggggctg gaagctacca 14640 tttgtgatac cgttattatt ttgatttatt ttagagttgg ggcctcgctg tgttgggagc 14700 tattattgtt atttctgttt gtttttgaga tgaagtcttg ctttgtcacc aggctggagt 14760 tcagtggctc aatctcggct cactgcaacc tccgcctcct agtttcaagg gattctcata 14820 cctcagcctc ccaagtacct gggactacag gtgcgcacca ccatgcccag ctagtttttt 14880 gtatttttag tagagatggg gtttcaccat gttggccagg ttggtctcga actcctgacc 14940 tcaagtgatc ctcctgcctc agcctcccaa agtgctggga ttataggcat gagccaccgc 15000 acccggccat tttttatcca tccctcccca cccagcctca ctgtcttttt ttagttcctc 15060 aaacttgcca gcttgttcct acctctggac ctttgcacac cccgtttcct cttgcctctc 15120 cgtttaacta agcgtgttca tccccggctc atccggcccc tggggcatgg gcctttcaga 15180 agccaccagg ccagtcccac actggcctcc tggtccgaat taaccaggcc tgtttgtgct 15240 tattctgctg agggggcagg ctgggggtga ggaaggggca tttcaccccc tttaaatgct 15300 tcaactcatt taaccttaat tgccttgttt tcatagacat ttgcgaggga aaaggaccaa 15360 attatagctt gaattgggtc ctactaatct taattaaaag ctctcgttta taatcaggac 15420 caggccccaa acgaggagca aaccgccctc aaatggcttg tttaaataac taagaccctc 15480 ctgataatca ctgtttagtc tgaaccaaca gtacacatca ccccttctat gtgtacttaa 15540 ttttttaaac catttattca agtggtttat tccacttgca agttccaact cgggcctttt 15600 ccaaaatgct ataattaaaa ctcttggggg aaataacttt gttgtttggg ccacagtata 15660 tcaaatatat tgctatgttc ctctttttgt gtgaaaagga aaaacatgac aaccttatgg 15720 ccatcagata tcacaaaatt agcatgtatg taatgaatgt aaataatcac ttcctgaatt 15780 ttatatcccc ggcgtctact tgtcaatcac tgaagttagg tagattacag agcatgttat 15840 taaaatgttt taacaaaatt cctagtaaca tactcagtga tccatttagt ttaacatcag 15900 aaaaacaaaa tcttaaaacc aatttggcct tcttaggaaa taatgtccat gaccttatta 15960 aatcattttc atcatcatta ttacacactt tattgaaact ccagataaaa tcctgctttt 16020 tgggaggcca ggaaaggcag taggcggtgg gaggctcagc ggggagagaa ggggaaattc 16080 ttctccttca agtcttaaaa catgcaatta tgcatgctaa cgtgtgctct gccgaagatg 16140 aaagtgctca agtccaagca gaccagcagg aaggaagaaa ttggatataa cttaaaattc 16200 caagttgctg tcagctagca attaggcaat gttgcttgcc agctctgctg cagagtttag 16260 gcctcttaca gagttcttgg agccaatgac cacttttagg aggaaaaata aaaagctcat 16320 gctactgcat ttaaacactg gaggcaagtt cacccctgag cctcagtttg cccatccgta 16380 aaatgtgtgt gcactggact ggattcagtt gagtatcaag aatgttcact gagcacctac 16440 tctgtgtcaa gcttggtgct ggggccaaaa catgtttcct gcctttgacc tgccttgtgg 16500 gagacacaga ttggaaaaga tgtgatcata acaggatgtg gaaagtgcag caatgaaaat 16560 acaaacaaga caggatgaag tagagaaagt gtatatctct gcctgaggag gggaagaaat 16620 tcaggagggc ttcttagagg aggtgtcctc tgggctaggt tagaaaagca tagcagaagc 16680 aggtctctga tgctccttcc agctgtgatg gtcaatggaa gcatttgtag caaggattta 16740 gaggtctgca ttttggtccc tcctaactcc gtgagccagc ggtgacttaa ccattctgag 16800 ccctggtttc ctcatccatc acatgggagc cacaacacct gccttacaga atgtgcattt 16860 gagtagagat ttgaggaggg aaggggcctc gctgtctgtg agaatgtgtt gaaggctgca 16920 ccagtatctg catgttggtt tttttttttt ctctaattcc ccatttctcc cagggttagg 16980 ggtctctgcc cccacctccc accctccatg tcctccagct ccccaggcag cagcccctct 17040 ctgccccctt cctctgggcc ctctcgcctc ctcttagccg cttcttatta cagtggctgt 17100 atttgttttt ccatcagagg aatgctaacc agcaaaaacc attatttcta agaaaataaa 17160 ccgtggactt gtgtgccttt gaatgctact gaaatggatg atggccttcc ctaaaggctt 17220 tgagacaaag aggactcggg gccttgtgtg aacgggcaag gtcaggaggt ctcagagggt 17280 gctccaagac aggcttccag atgggccagg gctgcagcct ctggctagaa agagtgtaaa 17340 accccagcca gctggttgga cgcctggcct aggttaacag cagctgctgg cgttgatcac 17400 tccccactcc ctccagggtc ttcaaggtgc acccctctct ccaggaaccc ccatgtcttc 17460 tgtctagacc tcctgcctct cgtacagagg gaagtggagc tgggagtgtg tccatggaga 17520 ccgggttcca gccctatgtg gcctgggcca agtctgtggg cctctccggc ctttgcatcc 17580 tgacatcaga gttcagcggg ggcaggagat ctcaggcccc tgggaccctc gctgtgggca 17640 gctccttcct cagggtgctc ctcgtttcca tggcgcccaa tgctggcctc agtctgtcag 17700 cttgaggggt gggcttcagt ggggcttagc caactgtccc ttcccactgc cagccctgcg 17760 ggcagacctg gtcctggcca gtctgtaggc aggagcacat gagtttgtgg gcatctgtat 17820 ctgagtcatt ccccgctcca ggctggcagc cccttgtggc cagggtccag gctaagggca 17880 aggggcctgg cccaggacag cactggcatg ggagggaaga aggcagggag gtggcctgat 17940 ccttcacaag gcccgcaggc cccagattcc tggttcacag agatgccgtc ttctctagac 18000 aattgtgtca aggtgaggaa ggtagagtct gggaccagcc tgcccaggtt caaatgttgc 18060 cttcaccacc ttctagctgg gtgatcttgg gaaagacaag ttttctgagc ctcagtttct 18120 ttttctatga gccatgggaa atgaagacct ttctgcctgg ctgtagggag gattaagcca 18180 gttaccatca aggtggtgcc tggtgtggag ttgccactgc tgttattttt attacaatgg 18240 agaggaagtc cacccgggga ttcggagaga aagggaatga aaccgaattg cactaggcca 18300 gctcaggccc tgcccactgc tggatcccga gatgagagaa agaagcccaa gctgagagcc 18360 ttgagttcaa attgccatga gcccccgatc tgctaagatt tgtctttcag ctcccttctt 18420 tgggcctcag ttacaccttg ataaaatcca gggtgctcta ggatccagct taccaattct 18480 aagggccggc ccaggttttc aggcaacttc ttgtttgtga ttgtcctcct gagcttggag 18540 gtggctgggc ctatggagca gccccacaga gcctgcagtt tttgggtctc gggcctcccc 18600 ttggcctttc cctaagggga tgggggaatg actgcctgta attggcagga gggtggaata 18660 ggggccttga ctgagggctg gcagaactag actcaagcct ggcaggttcc ctgtggtctc 18720 tcctggcttc catctcagag acgcgccaac ggctccattt tcacttgacc aggctgcctc 18780 agcaaccatt agtcctgatg ccagagccca ggagcagccc ccagcaaggg cttcagggca 18840 tttttgaggg agaaaggaaa taattaactg gtcttcatca tatcggtttg gtgggaaatc 18900 tcccctgctt cttgggagca acacacccca ctgtgacccc aagctgggca ggtggcattt 18960 gaggtcagtt cagagccaac ctccttgtgg tttcccttca cccaggcaga gatccctgga 19020 gatgcaacca gcccagagga gaagaagacc gacagcatta gcttgtttga cttttatttt 19080 taaacagctt tatcgcgata taattcacat accatacaat tcactcgtta aaagtataca 19140 attcaatgcc tttagtatat tcacattgcc agtccactac cacaatcaat gttagtatct 19200 gtttaattta ttgtatttta ttttatttga gacagagtct tgctctgtcg cccaggctgg 19260 agtgcagtgg catgatctcg gctcactgca acctccgcct cccgggttca agtgattctt 19320 ctgcctcagc ctcccgagta gctgggatta caggcatgca ccaccatgcc tggctaattt 19380 tttgtatttt tagtagagac agggtttcac atgttggcca ggctggtctc gaactcctga 19440 cctcaggtga tccacccgcc tcagcctccc aaagtgctgg gattacaggc gtgagctacc 19500 ctgccgagtc caatgttaga atcttttcat tactccaaaa agaaactcca tgccccttga 19560 ccatcctcta ccaccccgca agtcttcagc ccttccagtg ttaggaaacc tctcatctgc 19620 tttttttctc agcagatttg gtttttctgg agacttgatg taaatagaac catcgactat 19680 gtgatcttgt gacagagaca tcactaactc tgaagtcaag ctgcctggct cccttcctgg 19740 ctccccttgc atttgctgtg tgatctgagg caggacaggc aatgtctctg agccttggtt 19800 tgctgctgtg agatagacat ggtggtaccc agctctcagg gcagtcctgt gtgtggggcc 19860 tgcagactgc ctgacatgtc atgagagtcg gtcagcaagg ccaccgtcgt gattgttcat 19920 tcatgcaatg cccagaggat gcctttgaac atgctcgggc tctgctcgtt tctgaggctc 19980 aagctgcaca ggacacagtt ctcgttctca tggatttgca gcatcagagg acacagacac 20040 aagcaagcaa gaataatgct agtacctgct tgggctgggg gaggggctag atctgctcga 20100 agatgagcaa aagcttcagg gaggaggtga tgctggggct caggatgcag aggtgagtag 20160 atgtttgtgg aggggaagga gctccaggca gagggaacag catgagtcaa agtgtggagg 20220 tctgaagcca cataacggac tgggagaggt cactgagcag ctccaacccc acggttatct 20280 tgaatcacag agtgggaaag gggagggaac cttcccaccc tctggctgag ccatggtcat 20340 tgtgtgcagt taggaatgaa aaagtatata gatgtgtgtt agttttacgt gccctttgac 20400 ctttcctgta attaactgct gggcccactt ctggcattgt ctctgcagaa gggaaacctg 20460 atcgatggat gccaggggcc ctcagagagc gcgtctcatt actcagtcat tacaaaccca 20520 gagcttaacc ccgagccacc ggagacaggg gcttaatcct tcctgctagg cagcccaaga 20580 aactaccttc cctggagcat aattagccaa caaaccggat taagatttat tcatcaataa 20640 ggactcaact tcctaagcca tacatctctc cccgaatggt tgcctgatct aaggagggca 20700 cggtttttct taaagccccc agacaaagga gaggacgtgc tagcgcccag ccaggaaagg 20760 ggtctttgtt agagcgtttg gtctccactg ttcttgagga atgtctagaa aaatgccagt 20820 ttcaggggga aatgagaaga cattttcagt aatgatctcc gagagtagag agtgggatgc 20880 tttaaaaata cttaattttg agaatgtttc tagtcagtcc cgattttgag gaaaataccc 20940 taaaatagta ttaaaataaa atgaaaaggc tctctgattc attgcaatag gatcttttag 21000 aatctagaca ccacagagta aatgtatatt ttatgaagca gcaagaatca attttgaatt 21060 aaatgattaa aaaaaaaaaa aacacctcac cctatatggg ttccaaacct gcgttgctgg 21120 cacggaagca cagccatggg gttgtgtgtg cgcacgctgc ctttcaatac acaaaaagcg 21180 gagctgggtg acctttcaaa aattccataa tgagcagttc tctgtgctgc ttttctctgc 21240 tctattagat gctgggagct gtcttctgtt gggaattgag ttttcattaa aaacaaaaaa 21300 aaatccaagc aggggaagga acagggatgc ttggagtgaa ttgctggact tctcatctcc 21360 tgtgtcaggg ctctgaaagc tgctcagatc ttttgtcctg ccactttctc cattcatgtg 21420 aaccatccct gtcaccaccc ctcctcaacc tcaagggtag gtacagatct tggaaagaaa 21480 agtaataata cccatgaaat ctcttcccca cttttctcct taatgacttt ttggagcatg 21540 aaacactttt tttttttttt tttttttttt taaagacgga gttttgctct tgttgcccag 21600 gctggagtgc aacggcgcga tctcggctca tcgcaacctc cgcctccgga gtccaagcga 21660 ttttcctgct tcagcctccc gagtagctgg gattataggc atgcgccacc acgcctggct 21720 aggagcatga agtacttttt taaaatattc atctcacaca ccccaaggat gtggctccaa 21780 atgcgggaat agagcctgca cttgaatgca accactggct gggggcctga agacaaggtc 21840 ctcagcgatc ctgagcctca gcctcttctg tgtgacagca gctcttaccc tggcctcaca 21900 cacacagctg cctcactcca atctctgcct tcatcatccc acggctgcct tctctccgcg 21960 tgtctgtgtg tcttcacatg gtattcttct ccctgtatgt ctgtgtccaa tttccctctt 22020 cttaggacag cagcattgta ttaaggccca ccctaatcta gtatgacctc atctgaactt 22080 gattacatct gcaaagaccc tacttccaag tcagatcaca ttctctggtc ctgggggttg 22140 ggacctcaac atatcttttt gcggggacac aatttaatcc acaacagccc tttaagaata 22200 aacatccata gagctgtgct ctgtcccctc cattgcttta ccatctccct gctccacctg 22260 cctgtttctc gttctctggc tgtcagtcct gaaaaagtgg tctgagcctg atgagtgtct 22320 tggaggtctg tggtgcctct tccaggggcg gcgactcctg gatatgtttt tataataata 22380 aatccacttg ctttggcaaa tttttttagc tggtttgttt gtgtatttat ctcttaagta 22440 ttaaaggagg aggcttacat gattttagaa caaaatttca aggtacaaac atggaaaatc 22500 agggaaggtt tggtttagga gccaatgtcc tccatccagg acactgggag gtaaagctgg 22560 ctgccacagc aggcctgggg attggagagg aactggttgt tctgagagat gctcagcctg 22620 ggagaactaa ttggggatgg attaaggaaa gaaatgcaag cagcaaatat ccctgcactc 22680 tccagcccac tggcaattac tgtggcctac gttatgggga gtcaaaggca ggaaatggct 22740 agagttgttt tattgactat tcaacgatat ctttataatg ccttatgggt atggtgatca 22800 gatagtttat cattttaata atgaaaaggt taataactgc tgttaataat tacgccctga 22860 caacaggcat aaactgatac tgtgccagga aaattaaagt gtatgatatt ctctaactag 22920 gggaagacat cccctaacta ggaggtctga cgtttctcag accttaccac cattaaaata 22980 gccagttgga ttacatctta tagatgcagc aactccataa ctgattgtgt ttctttcttt 23040 gtcttggcat ttaggaagct cacagcccac cttctgtcat tgtgctacag ttatcaaatg 23100 tgtttttgta tattttcacc agctttatct tattcttcaa ccctcattta tttttcttca 23160 tactaacatc ttattctatt agaaaaaatt gttgtatgta ttttgtaagc tgtttggagg 23220 gatatttgaa ggaatcagtg agttaataga agtttggatg gatgaatggg taggtaggtg 23280 tttgaatgtg cgtgtgtgtg catgagcgtg agtgtacatg tgtttggata gaaaggtggg 23340 tatttgaatc aatgaatata cagatgagag gatttctcat ctggatggat ggatggatgg 23400 atggatggat ggatggatgg atgtttggat gggtcagtgc ttagatgaat ggaaggatag 23460 gcatctggtt gaatatttag acagatggat gcatgcatgc gtgtctggat gtatgggtga 23520 acatttggct ggataaatgg atgggtgaat aggtgattgg agaaatggaa gggtggtcgg 23580 cacactggat atttagatgg ataaatttta gcacaaatag ataaatggaa gaatggttga 23640 gtagatattt gaatggatag gttgagggtg agtagatgga tggatagtgg aagggtagat 23700 gggtgtttgg atgaaaggat gcatggctgg ctggctggtt atttgggtag ataggcatgc 23760 acacatgtgt atgtgtgtat gtgtatagac agatgcagaa caagtagaag gatagatggg 23820 taaatgggta tttggatgat tggatagtac tttctcagta cactgtataa atgtgccaag 23880 ggtgaaatac tgtatcatgt ataaagcatt ttgtcaatga ctggcatgtc acaggcattc 23940 taacttatta gaaaggacgt gggcttccta gactgaaaga cctttgttct gatccttgcc 24000 ctaccactta ctatgtgacc ctgagcaatt atctaacttc tctgcacttt agtttgttca 24060 accataaaat gaagttaaaa cacctacttc caaatgttgc tgtgagaatt aaaagggctg 24120 gtgtatattt caggagtaga tacctccttc tgaggtacaa gatgagagaa acttctttta 24180 cccaagcata gaataaaagt ccttttcctc agtctgattg atccaaccta agtcacctac 24240 caaccctggg accaacagca attgctagtg gcacgtgctg tttggataag actgttaagt 24300 ctccaccccc agagttagga ccaggccagc ttccccctga atcacctgct tgaaggagga 24360 aaggagggag ggaacagttt gggggctgct gagtcaaatc gggtgtgagg tgatactcat 24420 gctgacaggt agtgaaaata agtggccagt gggcagactg taaagatatt aagggtgtag 24480 aaaaaccacg cgttggtagc tgatttgatg ttaaggaagc agtggaagga aaacaatatt 24540 caccgggatg aggaacccca ggtaactgta ggttgatgag ttaaagttga gctttgttgc 24600 ctttggagta cctttggaat acccagggga agaggtggtt gcattagtct atctggggct 24660 ctggagaaag gtcagggctg caaacagaga ctgggaagta atcagtatct ctcagttttt 24720 taaaatctat gccggacgag gtggcttaca tctgtaatcc cagcactttg ggaggccaag 24780 gtgggcggat cacgaggtca ggagatggag accatcctgg ctaacatggt gaaaccccat 24840 ctctattaaa aatacaaaaa attagccggg catggtggca cgtgcctgta gtccagctac 24900 ttgggaggct gaggcaggcg aatcgcttga acccaggagg tggaggttgc agtgagctga 24960 gatcgcgcca ttgcactcca gcctgggcga cagagggaga cactgacaaa aaaataaata 25020 aataaataaa ataaaatcta tgtgcctttt caataaacat aaaatatcac attctccctt 25080 aagtttattt gtaatttata agtgtattaa atatcagaat taaaaacagc ccagagccag 25140 gcacagtggc ctatgcctat aattccagct actagggagg ctgaggcagg aggatccctt 25200 gagcccagga gtttgagtcc agccttggca acatagtgag gccctgtctc taaaaacaaa 25260 caaaacaaac caattcaaat gagctgcaga attgagaact gatgcaggtg cccctatagg 25320 cagattagga gaggacttct atctcttgat cctttggtga cccagcccag gctactttgt 25380 tcttccctcg ctgtggctgg gtggacacca agagtggctg cacggacacc aagagtggct 25440 gcacagccca gaccccttac tctggcgcgt tcacttctgc tgtttgttat cccctttgct 25500 ctgcagcatc tctggcaggc atcagggcag tgcttacacc tccagagtca gggagctcac 25560 tacctcctgc aacagcttct accttgcaga ccggcactcc tacccctgaa cgttcattgg 25620 ccccatggct tcccctcact gtgagtagct ctgctctcca gaccagcatg gagaaagcaa 25680 ggagttccgt gtctccctgc ggcagctcct ccagcaattg agggaagcta ggcctgcctt 25740 ctacaggctc tcttcttcta caggatggcc ccagccccac tttcgtagct ggaacccagc 25800 ctcaaaaatc cctcttctac gctatagggg agtgaccccg gcttcctact ccgtcgtctc 25860 gtgagatgca cttccggttc cacttagtgc tgcacttccg gttccggttc cagttcccct 25920 gtgggggaca cttccggccc tcctctctcc ccagcgtgtc tcggagcctc tggaggtcag 25980 ggtgactgcc ggttgagatg agtgaggcca gaggggtctc agggggatgc tgaagaccct 26040 gcagaagagc cggcaccacc aggctggcaa attctcgctg tgcctggtgc cctcccaagg 26100 acgccaggtg tgaccggggt taggcccctt gggctctgaa acccacgagt ttgaatccca 26160 cggattcgaa tcccatttgt gccacttcct aggtgtgtga ccttccacaa ggttttagcc 26220 tcactgtgcc ttggtttctt cagtgctctt gcaaaattgg aagtgagaat ggtgcctgca 26280 tcactgagtt aatgtgggat tgaagaggta atgacatggc cttacaagca ggacttgggc 26340 gtggaagcag ctcagacaag gttaactagg cgtgttccta tcattctcca gggtatctca 26400 aatctctctg gaactccaga attgatagcc ctttgacccc tgatgggaaa tgttgaaaaa 26460 gccttaaaac agcaaaaagg gtgaccttta tcaaggctac tggccattgt ttatgagaca 26520 ggagcctttg ttatagcaag gaagctggag cagttgaaat gcaggcatca gacactgatg 26580 tggaaagaca ctggaggagt tagtggactt ttctttcatt ccagagatta cacttcttgg 26640 ggatgtgcag ttaattttac tcaatacccc ctgcttcaag agagctagtt ttcggaaatt 26700 gtacactggc tccgtggagg cagaactagg tgtgaatctt gcctgttcac tgtggtagga 26760 actggaaggc accccacaca tgattagcat ttttataata cttgagtcct cagctcccag 26820 ggaggactga agtgaatact tgttgaatca tcccctaatc actcagatcc cggtggcttc 26880 catggtgttg ggagagggga ccaccaggct cttcttctga cacctctcat gcccttcctt 26940 ttgcagacat tgacgagtgt gagaatgact actacaatgg gggctgtgtc cacgagtgca 27000 tcaacatccc ggggaactac aggtgtacct gctttgatgg cttcatgctg gcacacgatg 27060 gacacaactg cctgggtgag tgatacagct gtagcctacc ctctgggcac accctgcctg 27120 ttgctttgct ccagcttaca gagttgggag ccatgggaag gttctccttt ctttggcttc 27180 ctgtattagt ttgccagggt tgtcataaca aaataccaca gactgggtgg cttagacaac 27240 agaagtgtat tgcctcgcag ttctggagtc tggcagtcca agatcgaggt gggggcaggg 27300 ttggtttttc ggagggcccg ctcctctgtc aggcttgcag gtggctacct tctttctcct 27360 tgtgtcttca tacggtcttc ccactttgca tgcaagtgtc tagtgtctct ctgtgtccta 27420 atctcctctt cttttttttt tttttttttt tttgagatgg agtcttgctc tgtcacccaa 27480 gcatgcagtg gtgtaatctc agctcactgc aacctccacc tcctgggttc aagtgattct 27540 cctgcctcag cctcccaagt agctgggatt acaggcgtgc caccacacct ggctaatttt 27600 tgtattttta gtagagactg agtttcgcca tggttgccag gctggtctcg agctactgac 27660 cttgtgatcc gcctgcttcg gcttcccaaa gtgctgggat aacaggcgtg agccaccttg 27720 cccggccagc cactgcgcct ggccctaatc ttctcttctt ataaggacac agtcatattg 27780 gagtagggcc cactctacaa actccatttt taagttaatt atctctctaa aggccctgtc 27840 tccaaataca gtcacgtttt gaggtactgg gtgttgaatt ccttcaacaa aggaattttg 27900 aagtgacaca atttggccca tgattttata tacctccatc ttctcatggt ccaaatacat 27960 ttttaagcca attgtataaa atttataaga ggtcgggtgt ggtggctcac acttgtaatc 28020 ccagcactct gggaggccaa ggcgggtgga tcacctgagg tccgaagttc aagaccagcc 28080 tgaccaacat ggcaaaaccc tgtctctact aaaaatacaa aaattagttg ggcgcatgcc 28140 tgtaatccca gctatttggg aggctgaggt aggagggtca cttgaaccca ggagacggag 28200 gttgcagtga gccaagatca caccattgca ctccagcccg ggcgacaaga gtgaaactcc 28260 atctcaaaaa caaaaaaata attacaagag tagtccacat ttgctgaatc aaattggaaa 28320 aaaggagaag agtagggaga agaaattggc aggcgtctta gttgtgctgg tgtgttttct 28380 atcagtcttc cacctgcatc caagtgtgtt tttaccatag tggtgatcag atagtcagca 28440 tgcatttgcc ctttgctgtt ccctttaata tcatgcgtac ctcaggcatt ttggttttct 28500 tttgagacag agtcttactc tgtcacccag cctggagtac agtatggctc agtgcagcct 28560 taacctctgg aactcaggtg atcctcccac ctcagcctcc agaatagctg ggaccatagg 28620 cacattccac tgctactggc taacttttgg gtttttttgt agagacaggg tcttgctata 28680 ttgcccaggc ctctggaact cctgggctca ggtgatctgc ccacctcgac ctcccaaagt 28740 gctgggatta caggcttgac ccgccacctt acctcaggca ttacttcagg tatttttatg 28800 tggcccctgt taccactatt tttctagttg ccccacagtc tgacaaatta ctaataacct 28860 gtatcagttt cctggggctg ccatgacaaa gtaacaaact agggcttaaa taacagaaat 28920 ggattctctt ggttaggagt ccaaactcaa ggtgtgggca gggtagttcc ttctgagagc 28980 tgcaagggat catctgttcc aggcctttct catagcttct ggtaatgtca gggattcctt 29040 ggcttataga tggcatcctc cctctgtctt cacattgtct cagctctatg tgtgtctggc 29100 tctgtgtcca aattttcctt ttttatgagg acaccagtcg tgttgcatta ggcccaccct 29160 aacaatctca tcttaacctg gacatctgcc aagaccttat ttccaacaaa agtcacattc 29220 acaagtactg ggagctgcga atccaacatc ttttgaaggg acataattca acctgtaaca 29280 gagggagttc aaagtctgtc acagaagaac aatatcttgt catgggaaac acgtggctct 29340 caaagcagac gtgtctgtcc ccaaggccct cttttgccac tggctgctgg gtaaccaggg 29400 cacagcaact ggagcccagg ggatatgggc atggatttgg caggagcatg tccgtagata 29460 cattattgat tgtctgggtc tcaggccctt gttggtagag ggaggctatg agaagcagct 29520 tcctcacagg gttgtcgtga gcagtgactg agataatgtc cagatggccg agaaaaaggc 29580 tcggcacagg ggactctcag cagccgagaa ctgttactat ctacatggtg tctgagcctc 29640 agtcttctcc agtctccaac agggataact gcgtaatcca cttcccaaga tcgcgtgtga 29700 ggatgaggtg acagtgtgaa gtgactagcc cctattaggt gctaaatagt caacgcaggc 29760 attactactc cagctgactc ggctgccttt ctgtggttag acatttagat tgtttgcttt 29820 tttgtttttt accatgagaa tccagaggtg gttctgggca taaaacattt ttttcccctg 29880 ttttcccaat cgtttcctta ggaatgcttc acaaaagtgg aaccactgga tcaaacgacc 29940 atttggtttt ttatggcttt ctaaaagggc tcagcaaagc ttctgttgtg ccagctggtt 30000 tgtgggtgtg tggtagagga tactgggtgt cctgagtgct ctggaacttt ccctcttaat 30060 ggggtgttag ccttagacct gcctgcctgt ttttgtccaa cccatgttgg atgtcagata 30120 agtttgttgt ggaaaacatc tgtgagcatg taattacacc ccgaataaat acccaagtag 30180 aggtccgagc atcaggttat tgaagcccag agaggcctgt gaagagctac ccgtggatgc 30240 agtgagtgtg ggggtagaag cggggctaac tccctagggg tcttcaaaga gaaggtagca 30300 ttgagtggaa cctccaaggt tggggataag tttgctagac caagggcaga gcctacatag 30360 acctgcaggc agcccctgag gctcagctcc tggtgcgtgc agggagcagc aggtgtgggg 30420 ctgtggaggt gagcagggca ttgactagat tgtgaagaac tgggaccaca caacgttgat 30480 cgtgccagat gccaggtgaa gtatcttcca agagttatct catttaatcc tcccaaaaca 30540 taagtgcttg gctttcttag ttgtttgctc cattttcaaa tgatagagag agtatgtttt 30600 ggtctctgat tagtcagtga agacagagcc gacagtccct ttgggacagc cagttaaaag 30660 caggcaatat cacccagcgg ccaagaggag agaccttggg aactgccagt ttgtggctta 30720 aattctagcc cttctctatc agctgtgtga cctttggcca gtcactttac ctctccatgc 30780 cttagtttcc tcacttgaaa aatggaaggc atagtcccta tctggtaggg ctcttgtgag 30840 gattaaatga gatcatggac gtggagcatg tagcagagtg tctggcacca aatattcaac 30900 atgtaaccag cattcatctg gtcactggct tccagatgag atgtgttgat gtggagtggt 30960 ttgatgcctc caagacctcg tggggaccag tccccaccat gtgcgctccc acggctgtgc 31020 ctgacacgtg gaactctcct tccagccact gtactcttac ctgtgcagaa ccacctgttt 31080 gtaaataccc tgttcttggc tacagcaagt actcccagtg tccccagagc ctgacgccag 31140 cagcctgcag actagcagtg agtctgtgtg ggcctttgtc tcaacaacat tgttttcaca 31200 atggattatg tttacactga ttaatttaaa agaactgggt aaggttcccc ccctcccccg 31260 ccccaccacc tctgagcaca gattgcaacc tcacgcggct ctaacttgca cacacagcag 31320 ccaagaaaag gctctctctg ttgctcctct gcctttagct gagggcagac ccttcccaac 31380 agagttcttt ctgttcaggc tttctctttc tcaagacaaa actccagctc tagagaagcc 31440 ggaccttggt tccaacaggc accaacccat cctgaccatg tgacctcaag ctagttaacc 31500 gacttcttgg agtctcagct ccctcatcca tgaaatgctg taagaactgg agtacctcgt 31560 actctaggat catggggctt aatcagtgtt ggcagaaata aatcatgctg taagagtcag 31620 ctgggcttgg agtttgaaga tttaggctca aattcaggtg tcaccgctca tgagttttat 31680 agttcgggac ctgttcctct agcccaccaa gcttcagttc ccctaactgt gaaatgggtc 31740 agtaatactt gtctcggagg gtcggtgtca tgattaaatc tgaaaggaga ttgtgcagag 31800 cttgtgtaca gatgtaaatt ctgtgcaggt gctggatatt gtcatcactt tccagcaaag 31860 gcttcaagct ggcaacccac agtccccatc tggcccacag acatgtttgg tttgtcccca 31920 tggtggtatc atttgttctt attaaattat ttgtcaacac ttaaaaatta ggggttatca 31980 cattaaaaaa aatcaatatt tctagcatca ttccatctca gccacagtta cccagcccct 32040 gacgtttgcg ggacttggga caggagtcca gatggaggcc cctatcccac atggctaaaa 32100 tattaaagta attaagaagc tcccaaacaa gaatgactct gcctcttcta ccttgacaaa 32160 tattcctaac taatgaccta gaggctagac tggaatttag aagactgctt ggattttgcg 32220 ccagaaagtg gtagcatggg caatgcctgc tccctccctg cccttcccac cctcggctcc 32280 accccacacc atgacgagcc tcagcacacc ctaatgcaaa tgtgcaagct ttggccattt 32340 accctgaaag cagccacctt ttgcctaagt cttactcagg cctaagtgta gtctgatagg 32400 cttaggaccc ttttggggga gttttagggt cctaaatacc cagcatgtaa tgtggagtgg 32460 taggcgtgtg ttccaggtgc tcatgactcc cctgtggacc ccttactcca tggtggtggg 32520 gtcagggggg tgctgctgca gccacaggag aggcagaaca gggaccccca aagtgtgggg 32580 gcccagggca acagcactct cgctcacatc tcactgtggt gctggcagca gctagagtga 32640 actacaccgc agctgcctgc ttcagagggg gtgtgtactc tcttgttcgc cacagtctcc 32700 accactccct attacttgca tccagctttg gccatttaac tacctgcttg aaattgtgct 32760 gcctggaaat gtttggaatt ctttgtgctg cctgacaaag cttcctgcac aaggttttgt 32820 ccccagtggg catttggtgg ctgtgagtgg cccactgagt tgttggaagg ttctctgtct 32880 ccgctgcctt gtgcattctt ggctgcctct gggcagtcac taaacctcac cccacagccc 32940 atcgcccatc aggaatagtt aggcccgttc gcacctcctc tgttttgtct caagaagtct 33000 gggtcaagag tcttgtccag ttgtaacatt cctctctgaa ccaccactga attccttagg 33060 gatgggggct gggataaaac cctgatcacc ttagaaataa acaggccagt ttgaaaagtg 33120 ttctgagctg attaggagaa atgaggctga tggcttacaa gttattttct tgcctaagtt 33180 ttcatagttg aaccttttct tttctttcga gtaagcgagg ttattttcct gtggagatgg 33240 cctgcctgtg actgtgtcct ggagggtggc caagtctgtc ctctggggag caaagccctc 33300 actctatttg acatctttat tgaggaattt ctcaaatata acagaaaatg acaccagagg 33360 gaattgaaac catgatgaga tcttgctcaa ccccaaatgg ctgcttttag ctgtgtaatt 33420 acttgaaata gcagtagttc tgtttgaaaa atattattcc aaactccatg caattggaca 33480 gcagagcaat atttaggcta atagaataag attgttttca tcttaaatta aaaccagcag 33540 tggataattt cttcccgtct ccacaaagca aggctcctct ttctctaaag ccattagttc 33600 acttagccag atgttttctt cgaccccgat ctttaccttg acttactgaa aaatacgtct 33660 ctcaagttgc tcacagtttg aattttggac ctgcctcttg gcactttttt tccctgttga 33720 agagaagtca tctgtatcca ggttcagaag cattgattta ttagccagct ctctccattt 33780 cattaacatt tattgagcac caaccctatg cccagccttg tgctgggtag accgtcctac 33840 ttgagtgaga ttcgggagct ttggttgagc ctcctgtgtg cctggatttg cccgggatgc 33900 tgtgctcagt tctcttgtta gtgctcacag catccaaaga cattagtgtc ttctttttac 33960 aaatgaggaa actgaggcct agtgagggga agtgacctac ccaagctcac acagacagta 34020 ggtggtagag ctaggactag agcccaggtc tgggattttg ccaatttcag cctgtaagcc 34080 tgccctgctg cccactcccg ccccatagtg cccaaactgc accagctccg ggaggctggc 34140 cagggcctcc ttgtcgtagg gtgttagata tgcacgcctg tatctatccg tgagtttggg 34200 agtcactgag agcatccaga aatcccagca cgtgccaggc caggcacagg cagggagtgt 34260 gctgaagggc cagcgggcac cccttgctct agagagctca taccaagggc gcctccaccc 34320 catagctcgt tcagcctcct tgggccaagg gcagagcttg tggccttgtt taggcacctc 34380 acatcatcct tgagccaccc ttgggacctt gtcttacccc atccaactgt acggagccct 34440 ccgctccagc accctcctct catggccatt gcttccacag tagcttgaga cccctctggc 34500 cagggcccca ccagcctccc cccaacccca tttctcaccc ttgcttagct gtgcccactg 34560 ggccagcctt ccctgtaccc gcagagtcct acacaaatct gttgacagac tgctactccc 34620 cagcagggat ctggtgaggt cctgctcatc cttcaagccc caaccaaacc tccccttgct 34680 cagaggtctg ctgtgaccca cgccacacag ttacatctcc actgcagctc tgtgtcatgg 34740 tcctctcttc ttccccaaaa gcagaatttg tcttgtttac ctttctgtct ttcttcttgg 34800 aacctagtgc agtgtcagat atattgtagg catttagtaa atatttgtag aataaatgaa 34860 tgaatggatt tgtcaaaatg ccttgtaatc taaaaaccct ctcacctaac aagcctctga 34920 ttttgcacca gaaagtggta gcacgggcaa tgcctgctcc ctccctgcct ttcccaccct 34980 tggctccacc ccataccacg atgagcctca acacacccta atgcaaatat gcaagctttg 35040 gccatttacc ctgaaagcag ccaccttttg cctaagtctt actcaggcct aagtgtcgtc 35100 tgataggctt agaaccattt gaggggagtt ttagggtcct aaatacccag gatataatgt 35160 agagtggtag gcatagggca gaggtaaaga ttaattagat gagatatctc tcgcagggct 35220 cttaggtcca tgaggaagcc agaaatattc acaactctaa tgaagggtag aaagtgctat 35280 attagggcca ggcacagtaa ctcatgcctg taatcccagc actttgagag accgaggcgg 35340 gtggatcaca tgaggtcagg agttcgagac cagcctgacc aacatggtga aacaccgttt 35400 ctactaaaaa tacaaaaaaa aaaaatagcc agatttggtg gcaggcgcct ctagtcccaa 35460 ccacttggga ggctgaggca ggagaatcac ttgaacccgg ggggcagagg ttgcaatgag 35520 ccgagattac accactgcac tccagcctgg gcgacagagt gagactctgt ccaaaaaaaa 35580 aaaaaaagtg ctacattagg aataatacta aagccttcca cctagtattc atccatttgt 35640 ttattccaaa aaaattgttc tgagtgcctg ctatatgcca gacatggttt tcagtgctta 35700 ctatggtggt gaacaaaggc tacaacatct ccctgcttat gaacttacat agaggagaaa 35760 gacagtgaac atgtgaacat gtaactcagt aacttcagcc aggtcagagc cactgaaaaa 35820 aataataaaa caaataatgt gatacaaagt gatgggggca gggtgacagc attgggtagg 35880 gtaggattcc agttactatt gctgcataag aaaccacctc aatatgtatc aaggccaggc 35940 ttggtggctc acacctataa tcccaacact ttgggaggcc aaggtaggag gatcacttga 36000 gcccaggagt ttgacaccag tctgggcaac atagcaagac cccatctcta cagaaattta 36060 aaaaattagc cagggatgga ggtgtgcgcc agtggcccca gctactaagg aggctgaggt 36120 gggaggattg catgagccca ggaggttgag gctgcagtga gttatgtttg cactgctgca 36180 ctccagcctg ggcaatggag caagatcctg actcagtaaa actaaaaaaa gtttttaaaa 36240 aatatgtatt gaaaaatcac tatgtccccc acaaatatgt acaattatta catgtccatt 36300 ttgaaaagta aaattaaatt tttaaaaaac tacctcacat ttagtggcat aaaatactat 36360 tttgctcatg aattctgtgg cgcaagaagt cagacaggat caactagtct ctgctccacg 36420 gtgtctgggg cctcagctgg gagacttgaa agctggggat gacttgatag ccaagaactg 36480 gaatcatctg gaagcatctt tgctcacagc tggtggtggt ggttggctgt cagccaggac 36540 actatgggca gcctctttat gtggtctttc cacatgggct ggtaggagct tccgcacatc 36600 atggccgctg ggtcctaaga cgacagaatc ccatgcttgg cagtttgaca gtctagcctg 36660 agaagtcacc tccaccaatg aggggggtaa cagaggtctg cccggggtaa ggggaggaag 36720 ccccagtgag agggaggaag taccacatga aggtctaggg aaggtcctct gtccaagcag 36780 aagggggaca agtgtggtag gaactgttag gagtttgggg atgggccagg atgcctggag 36840 gatcaggagc gagggacaca gactggagat gaggcaacga ggcgggccgg ggctgggtca 36900 ggcagggtca tatcgtctcg agaaaggggt ttggatttta ttctgttacc tgggaagccg 36960 tgggctattt tcaccaggga ttgacatgtt ccagtggaca ttttaattta aaaagcgctt 37020 ctggctgctg agtagagagg cagagtggct taagcaggga aaccactgca gtggcctggg 37080 tcagagcggt tggtggcttc gttcagggtg acagtgggag aagtggtcgt tgaactcaca 37140 gtgtattttg aaaacagttg acgggagcag ccagtggatg agatatgaga ggtacaggga 37200 gaagagagtc aaaactgatg attgggtttc cccggagttt ctaggggctc tgctgctgtg 37260 gctgagatgg ggaaggctag ggggaggaca gactgggtgt gggggtggac acggaggtac 37320 aggactcagg tgtctgttcg tctgagttct gtttgaaatg ataagcagcc atcgaaatgg 37380 agatggtgca caagcttaga agtctgtagt caaacccggg ggaaaatgtg agggtttcta 37440 catggcgtct agatggcttt ggaagccaga tattttaata ttcactcatt tcgtaaagat 37500 ttcacaagca cccaccctat gctgtgcctt gcttggagct cacaattagg agaggtatgg 37560 ccttatttcg ggccctcaag gagcatcaga aatcgatctg cctggctttg aaccctggat 37620 ccatcactta ctatgtgacc ttgagcaagt aattctgctt ctctgggcct ctgtgtactc 37680 ctgcatgagg tggggctggt aacagtgctt atttgacaga gatgatgcag aggccaacga 37740 gatgagcttt gtaaaacaca taccatagta cctagcacag ggcaaggtct caacagatgc 37800 gaatgagcta attaacattt attcctagtg tgcaaagcca gaacacagtt tagggaaaat 37860 ggatatacct ggagctggtg aaggtgcagg gggcgagcct gggcctgggc cgtgtgggaa 37920 gccctttgcc tgggccctgc tcctcattcc tgccagatga gctgctgccc acggtccgct 37980 ccccacctgc caaatgctct cccagcctct tgcgctggtt cttgtactta ctgtctgttg 38040 actgaggggt catgtgacat cgcgacttca atttgagctc tgctgtgttc ttattttgta 38100 acttgggaca catcatctca tttctcagag tcggagtttt ggtctctgtg aaatggggtc 38160 ggtccctgtc tgttaggatc agttgaggag atggatgtgc aagtggcact tgaggctgcc 38220 aagtggaggg gtagaaaagg aggagtagga ggggccctcg ggggactccc gatggggcct 38280 ggagcccagc tgcaccctgg gggaggaagt caccggcgag tgcccagatg ctccgtgcag 38340 gcgccgcgct ccagctctcc ctccgctggg ctgatgaaag ggcctgcgcc atcgcggcct 38400 tttaaaggag gccctcttgt cctggaagac agctggagac aacatgtggc tccctggaac 38460 ccctaacgaa ggctcgagtt gctgctgttt atttgtcttt atacttcaac agctcaaata 38520 catttcttgc tggaaaaaaa aatgctgatc atcttaatgt aaaactaaac agctttggac 38580 agtcatatac ttactccata aacaccaata ttttctaaag taaactcaag aggtttcttc 38640 ctggtctctt tcgttatgcc cacctactac cccaccacct tttcccattc ttggcccact 38700 ttcaggtgct ctaaacacgc tcagttggag gcatttgctg tcagagtaca agacagatcc 38760 aggcccgcct ctcctctccg ccttctacag ctgttaatct gaaagaaatt atttggcctg 38820 agagaaagag actccctgga cagtgttgta catctttata gactcgcttc cttcttttcc 38880 caaatcgcta caaaaaaggg gagaccctcg agtggggtgt agggaggcag actgttcaga 38940 cctttgtgtg tttcggggtg gagtggcctt tgacagcctc atgcccatgg cctgcttggg 39000 attgggtggg gggactgtgg ggtgcttatt acagggggcc agatggttct cctgccagcc 39060 cccttctggc ccagcaatca gggcagaatc agtggcccac agagcagaag tcaggctcct 39120 taggccactg acttgctggg agaccttggg aaatgccctg cctctttatg cctcagtttc 39180 cctgtcatat gtgaaataaa aagatgggat ttgatcagtg gttttcagat gctgtggggt 39240 ttatagcagc agaaatcttt tttccgaagc ggaatcatgc aggggtctca cgctgtggct 39300 gaacgggaga caagactggc cacagttaga gctctgctcc ccatggaacc tgtctctacc 39360 tctgcaaagt tcctggagcc tctggacctc agtttggaac cccctggctg ggctgctggg 39420 tcagagccct tctccttcca gcatcccgtg acctggcagt gcggtcgtgt gattggcccc 39480 agggacagtg gcagctcagc tcttttccgt gtcctccttg tcccagcagg atgcagtcgt 39540 tgtctgcgca gctctccttg tttctcagaa ctgtaatctc cagcatggcg aacacttttc 39600 ctctccataa ccatcccgcc ctttcctcct ccagggtgtc catacacctg ctgttctgca 39660 ctgagcgccc ttccccagcc tcctgatgaa cgcttagttt ggctggcccc tacttgttcc 39720 tcagggctca ctcaggtgag gcgtcaaccc ctagagaaga cctctctgag ctgtacagcc 39780 tcccctaggc ttccctctga catggccctg agctcctggg actggcactc aggcatctca 39840 ggggagatct ctcttccttc cttgggaatt cctcgagtgc tgagctctgg attggccaag 39900 ctctttatcc aaggcctgca aaggccaggc ccacagcagg ctcgtttgtg tggtggagga 39960 tgggcgggtg gcagggtaac ggggtagaat gttggattct gaccctcagg aggcaaacga 40020 cttgacggtg gcaggtgcac agacctgccg tgggggtcat cagcacactt ggagctgggt 40080 agaagcgctg ggaaagtctc cctgtctccc tcggccagcg atggcctgtg actccccagt 40140 ccacttctcc gtgcctggct ccttctggtc tctgctctag acacagggag agcatggact 40200 tgggcatcag acacgttggc cttgactccc actcccttcc tagctctctg ctctcggttt 40260 tctttcctgg aaaggggcat gctggtgttc ccaggacagg gctctgggga tacagagaag 40320 ggtgtacgtg aaggaaggtg gcacatggtg ggcctcagga cccttcacct gctcgtccct 40380 tcccactctc cctgtgcttg tacattcagg tcagggattg catccctgta tgaggccacc 40440 ttccccttgg taggagtgtg tgttcgtgat cccatcctcc ctccactgga ttgaaatctg 40500 ttgtcactgt gcctggtgcc accctacctt tgtaggtctc aatttggtgg cttgaggaag 40560 aagccccgct ctgtctcaga gcagagaata ccgagtccat aaacagcaaa gaaaacactc 40620 gctgcagaca cttgccttcc tctgttcctg tttgcagtcc ctgtgccaag agcttggtca 40680 gaactccaga aaataaaaaa taaataaata aataagtgtc ttgtgaaggc tccttaaaaa 40740 taccctgcca gcaaaacata tgcccccaaa ccagacacgg agccgtggcc ctaaaagggg 40800 acattagcaa caattaaggg catctcaacc cagtccagta ctgcgtctgt caatagtctc 40860 gcttaccttg gagcaccctg ggccctgggt ggcgtttggg gtcgccctgg acgtttgctg 40920 ggcctggctg catcggggca gatgctgcag tgaccctcct cccccagcac cgggacaggt 40980 tccagctgtt tatagtggcc attagccagg cctgtgcatc aggctgccct ggcacccctc 41040 cctgtcaccc acctcatccc aaccacatac agctagaaat agactgctgg cagagacgcc 41100 ctgtgcctgg ctggcactct ttatttgtgg gaagtgggca gccatggcag caacccagct 41160 gcttggcctg gggtctttag taacctccca ggtgctactt taatgatggg gagaggatcc 41220 cacaggcttg ccctcccctg gctcatctgc tgaccgccag ggggtcagac accagtggag 41280 tcatttggga cccacccgtg gtggaggccc tgccgagtgg gaccctcccc agggcctgtg 41340 ttgccattgt gggggtctgg cttccttggc ctggcagctg gccctgctga cactccagcc 41400 tttctgtttc tccctgtgct cccagcaaac taaatattaa gcctgtcccc cggctcctca 41460 tgccctctgg gcctctgcac acaccattcc cctacctgca gaacctcctc ccggcctgtc 41520 ccggacaccc cagctcttcc tcctgagcct cttccccagc cccccgggca gagggacctg 41580 ctccctgcat tctgctccct tgccctccct gccaactctc aggcctgcca gaatcagacc 41640 aagctgcaaa tgtctgttta cttatccatc agccacacgt gcaataatta tacagaaaca 41700 ctcagagaaa tccagagaaa agacaaaatc attcccccat ttctcacccc tccaatagag 41760 caagcgtttt catgtcctga tgtccgtgtc cagtgtcacc tgggcgtgga cagaactgtg 41820 tgtggtggca gtcacccatt gaggtttatg tgccgcttct cctccgtatt ccggcaggac 41880 tctcttcact gttgatgcag aatcacgtcg ccaagatgga atggaatgaa agcccgggac 41940 agtgcgggca gtgggggtga ttatcgggtt gggacagcaa gaatgcccca atgctcttct 42000 gtcaggacat gccccgggtg cccatatctg caggtgaggg gcctctgaga ttagttagac 42060 tcactcttgc cctcagggag ctcccaggcc acgtgcagaa atactcccac tatggtgtcc 42120 tttgtgtaat taatactagg ggtgtgcaaa gggatggtgt ggggtgggtg actcgcccta 42180 cctggagtga gtggagggtc ccctgcgggg ggtggagatg gggtgaaggg aggacatttt 42240 aggaggaagg agcagcatgt gcagagcctg gagatgggaa gggctcggcc agggagcaga 42300 gtgggttcag ggcaggtagt ggtggtaaaa aggcagtctc tgtcaaatga gccatatata 42360 ccatgtgctc tcctggtctt agacccagag attacacaca cacacagaca cacacacaca 42420 cgaccaaccg cacttctcac caccaaatgc acctttctct gcactggtcc tcatgtggct 42480 tagagagacg ctctctgcct gggttcagcc tgcctgttcc tgcttctcac agcacactct 42540 tcttgtcctg cagggctctg accccactat ggttaataga cactggtctc ccagtgtcct 42600 caccacctct ctttcctaga atggcagctc cctgagggca ggccttggcc tcgtctttcc 42660 ctgtttaccc atgcaccagt gtggtgcctt gcacccctgc caagtgactg agtgaacaaa 42720 tacatgtgac taatcacaga agttcgctgg agatggatgt ggccaataga aaagacggtg 42780 gcagatgagg ccaccgcaag tgcagatgct gtacggcagg agagtcagtc agttgtatgc 42840 aggttaacag gggtcttcag ggagtcatga gaaacaaaag ctcacagtcg ttgacccagg 42900 aatcccactt ctggggagct ctctgaaggc aataatccct taaatgaaaa gggccgtagc 42960 tgcccagctg cgtccttcac gggggagttt attaacaact gcacgagggc gtggaagagg 43020 agcccactgt ggactgcaca aagcagcgag tcagaagtgg aggcagggcc aagccacagc 43080 actgaaggcg ctttagctca gctcgccgtg gctgtgcaca gatcaactca ttacatttag 43140 gagaaaatca gctcatgcaa aaagacggaa acaaaataga tgctcctgac tgtggttctg 43200 tctaaactgt aggattgttg atcagctttt ccactgtttc tccgaattcc ttatcggctc 43260 agaatcttaa ataataaaac agttgtattg gtcaagtgat aggaagccat gctaggtttt 43320 tgagaggagg agaactacag acagaatgtg gccacaaact cagagacagg ttggctgtgg 43380 ggaggcctgc gagcgtgcca gtgcctcagc caagcgagtg cccccttttc cgtgaagctt 43440 cctggcaccc ccacccagcc ctctgccact gccttctgtg gcctgccatc tgcctttctc 43500 cggtatgtca gctctgatga gacaaaacta ttccttagtc ctggttgttg ccaccaggcc 43560 caccccgggg cctgacaggg agggactgct gagtgcagga aggaacaagc ccacatgtgg 43620 caggcccagc tggggagcca atgcagggca tggatggggc aggaggccaa gcggctggga 43680 tcagggtatg gccacaggcc tggcgtgtgc caaggacgct cacgctcaag gatacctggt 43740 aggtgaggac aggtgtacac atggagggtg ctagcaagga ggaggaagag aaggaacagc 43800 cgcacagccg cctggcaatt tcacatagct ttggagggtg gaagaaaatg cggacttcca 43860 cgggaaagaa ttagtccctg aaggttagaa ttccgacggt accgaggctg ggaaatggat 43920 gctgggaatc aatcagctga cttggctgga gtctggcagg atgaactggc cagaggacct 43980 gtgtcacctg gggtgtcgtg ggagctccgg cgcccctcct tggttcgggg aagtttggtt 44040 ttgtttttca acaggagtgg gacttgccct gccgccccat ccaccggcct ggaggtaatc 44100 acatgcagct gggcctgggt aggcgcagag gcgcttcatt aagcgtcccg tgggagcgtt 44160 tcctccttct ttccttacag cttctcgctt tggttccatg atttgtttgt ttggttttcc 44220 tccttccctc tctccagtcc tccattctta tccccatcaa aagaaatttt taaaaactcc 44280 agtgcctcct acagatgtcc agccaggatc acattcacag ctgcactgtc agaggcctga 44340 ggggatgaaa gcaccccgtt cccagcctgg ctctgtcact cacttgctgg ggactgtggg 44400 caggctgcac actgcttgga gctcccattt acaaaacagc tactgccctg ggctgaggtt 44460 aactgagata actgtaacaa agagtgcctg actctgagca gggaccccag ccgccccctg 44520 ccctgcctgt gatctagaag ttcaaggagg aactggcctt gccataggtg gtctagcaaa 44580 gtgagtgaaa tgtagttcgg taggggatcc cactgtgtct ccagaccgct tccctctcca 44640 ctcacttcct gaaactctgc ccagctcaag cagcttcttt agtgggagac tttggtcctc 44700 atgtcagtaa aggtgccgac aaagcaggag gagacgctga gctgcacccc tcttctgagg 44760 ccccccaaca tggatcccgt catgcactga gcaccaaagc cacaggctgg caatgactgt 44820 gagggtacct ggttccccat cgcgatctcc gcacaagctc cccactctcg ggcaaggcta 44880 aggcggcgga tgagcacagc tcttctctga gagccttctc tggcatctcc tgatgtcagc 44940 ccctgaccca cccacgcacc cacggcccac tggtagccag cacatgctcc tgtcactcat 45000 ccagagctgc ttccttgagc aggtcctggg gctgcagggc ctcatggcag cccctctgca 45060 gccacacttt gcagcatacg gcagcgaagg ccatgcagct catccttggt gggacggcct 45120 ttagccaggg cctgtggatg tccaggccag aagcgccgtt ccccacccac acttttggaa 45180 gtgctcagtc cgttatccag tccgcagaca tacatcatgt gccccgtgca ctgttcaaaa 45240 ccctgggata ctgtgatgct caaaacagac agggtccctg ttctcagggg ctctgtgttg 45300 cctgggggta gacagaaaca gtcacaagga agattccagg tgggtggggg cgtgctctga 45360 aggaagcagg ggagggacac gttgcagaat ggcctgtctg ccactttagc ttagtggtca 45420 gagagagcat ctctgggaaa gcggcacgtg agctgaggtc tgaaggagaa ggaggaggca 45480 gccgtgccaa gacaagcaaa gaacattcca ggcagaggag caaatgccaa ggcctggaga 45540 tgggaacagg acagctgggg tcaagggaga gcaggacaca gcagcctggc tggaggcggg 45600 tgagcgagga ggagcccggg gggacgtggg cagagcagtt cctgtgggct tggtggccgg 45660 gaaagggagt tcatgtttat gacacctttg tgggctttca ggcaggggga tggcatgagg 45720 tccatgaggg atggaggatg gacagaggca ggatggaggc agggagttcg agaatccagg 45780 ccagagacga gggcgactgg cccagccgtg gcagccctgg aggggagcga atgtgttgta 45840 ctcgtggtga atttcacagg cagaattgaa aggactggac ctgctaaggg cttcaatgtg 45900 gggagaaagc agcatcaaaa ataactacca ggtgttttgc ctgaagcaac tgtgggttgt 45960 gtgaccattt gctgagctgg ggaaggctga gggcagactg agctttgtct cattctattc 46020 tgcttttgtg ggagggggac ttgggagttc agcacgcggc ccatgaagtc tgtcacgccc 46080 gcaggatgtc cacgtgcagg caccaggtca gctcttgatg tctaagttgg agggtggtgg 46140 agctggcagg cctgggggtt tgggggcaac cttggcagat aggtagccaa gggacagtgc 46200 gaaatctccc aggaacaaaa tgtagatggg gtgggggcga gggaagagcc tgagagaagc 46260 ccaggcccca ctgacctgca ctgaactcct gagtacctag tgctgcctga ggctgcttga 46320 aaggaggtgg tgtccacaga ataggaaaaa gtatttgcca atcatatatc tggtaagggt 46380 ctagtatcca ggatgtataa agaactctta caactcaaga catcccagtt taaaaatagg 46440 caaaggacct gaatagacat atctccaaag agatggagac gccacgccca cctggagtct 46500 ttgtgactgt ttctgtctcc ccacagacag catagagccc gtgagaacag ggaccgtgtc 46560 tgtcttgagc gtcgctgtat cccagggcca tacaaatggc cactaagcat gtgaaaagct 46620 gttcaacatc attagtcatt agaaaaatga aaatcaaaac cataatgaga aaccacgcca 46680 cacccactag gatggctgtt aaaaaaaaaa aaaaagccca gaaagaacaa gtgttggcga 46740 ggatatggag aaattagaaa ccccatactt tgctggttgg aaatgtaaaa cggtgtcgcc 46800 cgtggtaaac agtcatttcc tcaaaaaggg cacacatgga gttaccagat gatgtgacag 46860 tgccaccccc aggtatccac ccaggagagc tgaaggcgta tacccccacg aaaacttaca 46920 cacagtgttc agcagcaccg ttcataacag ccacaaagcc agcacaaccc ggatgtccat 46980 cagctcacga agagatacat gaaatgtggt ctgtccatgc aatagaatac tgttcagccg 47040 taaaagggaa tgaagtgctg agtcacgcta cgacatggat gcagcttgaa aacatgctaa 47100 gtgaaggaag ccagacacac aaagacaaat atcgcatgac tctctttaca tgaaatgtcc 47160 agaatgggca aaccatagat ggaaagtaga catgtggttt ccaggggcga aggggtagga 47220 attgggacta accgaaaacg ggcacaggtc ctctttctgg catgatggaa atattctgga 47280 attagtagtg atggtcgtgc aacacggtga atatactaaa aaccactaag atgtcggctt 47340 aaagattgtg aattgtgtgc tccatgagtt ctatctcaac cagaaacggg attggagaaa 47400 tagcagaggt cacacgaaca tagcatcaaa agtcccaccc acatcctcca agcagaccat 47460 gtgcacagct ctgtccactt ctgggccaat tgtgagtgcc ccagtaagct gggatcccca 47520 gagaagggcg acctgggtgg tgagtgtgcc agaagcttat tcaggaggga acagtgtcag 47580 gagccgagcg gcttcacttg gagaccagaa ggctgaggcg ggtctgagtg ctcccctctg 47640 atgtggtttg ttgttgcttt tgcattttgg aagggacttt gctgtcactg gagtacgttc 47700 gtacccgtga ttccctgagg ccatgagcag cggcttcgtg ctgcacctgc tcacactcgg 47760 tggtggtctg tgtgtgccag gcgctgtgca gagtacatta cctccatcac ctcctttgac 47820 tcccaaacac ctcagggact tttatccctg ttttatagag aaggaaacca aggcccaaaa 47880 tggtgaaatg acctgctcaa ggtcacagag caagtgacca gcaaagactc actgaatctt 47940 ttttcttttt tttttttttt gagacggagt ctcgctgtgt cgccccaggc cagagtgcag 48000 tggtgcggtc tggctcactg caagctccgc ctcccgggtt cacaccatgc tcctgcctca 48060 gcctcccaag cagctgggac tacaggcacc cgccaccatg cccggctaat tttttgtatt 48120 tttagtagag acagggtttc accgtgttag ccaggatggt cttgatctcc tgaccttgtg 48180 atccgcccgc ctcagcctcc caaagtgctg ggattacagg cgtgagccac caagcccagt 48240 cgactcactg aatcttgtac tccatctggt atgacttgta gagcaacagc caggtcccat 48300 gggcagtggt cacagggcag catcacgcag acccctttga ggactggcca gcggtctgca 48360 ctgggcggta gactcccgtc cttccctaga gatgcacagc agggggcggc agggcagcgg 48420 ctgggctgga aggcaggact caggttgcgg agagcagagt gagcagaccc cagcggccag 48480 caggcttcac cacctctgcc ttccctgggc tggcttgctg ggtttggacg tgagcagtga 48540 gcttgctggt ctggaaagct gaccttacca ttcatgcgcc tcatctccca ccctgagctt 48600 ggactcaggc ccaggccaag aggttggctc tgtgtcttct gcacacggcc aacctgctgg 48660 ggaatcagga gccccaggga agacctcagc tgatgcccag accaggaagc agacaggtcc 48720 tgggagaccc caggcatacc tcctgccgcc tgtgccagca gctcttgaca gctcggagag 48780 tgttctggat ctggcagaac ccaggcccca aagctctaag acccgtgtgt attttaccca 48840 aaatctaatc catctggttc tcatttattt acacttaact catcaaatgc aattttgcaa 48900 gagccgctag atagccaaga ggcttttctg cctaagccgc ccttctgaaa ggagccggca 48960 ggcggtgggg gcctcagccc cctgggacca ggtgggagct ctccgtgctg gaggtggagt 49020 tcgcttcctg agatgggctg ggcacctctg cctctgtttc tagaccttcc gtgggagctg 49080 ggacaccgga gccagtggag ggcctgacac acagtaggct cttgacagcc atgaaaacat 49140 gggtgggtcc aagcagaaca cggagtctct gtttcaaatc gggaaatatt tgcgggaaac 49200 acaaagcagc cagagctgga tccagaagta atttttagtt gttataaata actgtgaacc 49260 tggactcttg gtccaaagta gaacgaacag ccagctatta ataaaaacaa acatcagcat 49320 cttgggccaa gaagcacacc tcccggggaa actggtcctg cctgcagagg cctttcggaa 49380 gcgggtcaac ctatggcctg ctgatgtcag ctctggaaat tcttcttgct ggaaaacaac 49440 catgtcaatc acagcacagg ggtcccctcc cacacatcac ccttcagtgg ctggcagcag 49500 gtggaggtgg cctgcgcctg tgaggaccga gtggagatgg gcaagagtca cagctgaggg 49560 ccgtccgccg ccaccccggc ctccagagct gtgctcatgc tgggtactgc acagtgagga 49620 ggtgggacct gaccccagag accctgtggg accaaggtgc catgtcctgt tccagccaga 49680 ctcatcacag cagccactgc ccatggagaa gggattggga gggagaggct ggaggccgag 49740 acccaggaga agtgtgcagc ctaccccaaa gaggaagctg aggtccaagc cagggctgtc 49800 tcatgggagc cagggagatg gacgggcaag gtggcgtgga aaaagtcagc agccttggtc 49860 agacccttgg gagaggggca gaagaaaggg gcttcgagaa caacagggtc ctcaggcctg 49920 gtggctgggt gggacgaggg ccagaccctg accagtgagg cccctctttt gtgctccaaa 49980 tgctcagcct ttcttgactc ctgtccttcc cttctcccac ctctgacctc ccccagctct 50040 gcgggctgaa ggaatgggag ttcacagctc acggggagca gccttcaagg accttcaggc 50100 tccctgtctt ttgtcccata cctcactgga gtggtctttt tccgaggggg tctcccagcc 50160 ccacctgctg aaggcccctg tggcacggcc caccaaggtt ccaccttctc ttcctcccag 50220 ctcccctccc ttgcctgcca tttcagcctt ggcccggaag agggaagggc tccggcggtt 50280 cgatggcaca atcacagata cagttgtaca tcaaaagagg ctgtggacca gtgccttcca 50340 gcctcaacca ggccggtcca gacagctgtg aaaggctcct cccaggaccg ggcatggagg 50400 gcccgctctc cactctacct cccccgtctc tctcaccagt tgaaaggatt tcctgaaagg 50460 agcctcctag agtctgcccc agagcccagg ggacctcctg tctctttgta gctaagtccc 50520 tgtgctgtgc tgaggagctc cgtgccttct gggaacattt agctgtggtc ataaataaag 50580 atgaaggacc atgagctgcc agcaggattc agaggcggga cactccccct acccctccta 50640 gagccgccca gggattctgg accccggatt ggaaacaggc ccactcaggg gcctcactac 50700 acgcaggctc agccctggcc caaggcctca gtggtttggg acactctgcg tgtcaggctg 50760 cacaaatgtt ttctgcaggg actgtccccc tgctagttgg actgatgtgg ggacccgaac 50820 agagctgggg tttttgagcg ctgtgtgggg tcgccagggt agggtgcagg ccacagagca 50880 gcctcgctca ctctacatgc ccacggcctg gctctgctgt tcctcttagc ccagcatcca 50940 ggaccctgtc agccaccttt ccctggttgc ttccagaact ctcctcctgt tagagaggct 51000 gcaggccctt ccctgtctgg gccctgccct gccccttcca cgagcctttg ctttcagaac 51060 acctccgcct cctccaggat ccccaggctc aggtcacacc tctctgctgt cctcaaagca 51120 gcttgtactt cgcctcttcc aggaagcctc ccatctctgt gctctggccc agtgccctgg 51180 agcttggtgt ccctggcagc tcaggggtag tgtggcacag agtaggtgct tggtgttcac 51240 ggagtgagtg aatgaacaga ggcgtttcag gtggattcag aaggcaagaa aaacttcggt 51300 ctggacaagg aggggaggca gttccaggag gagggtggca tgcacactcg ggcagaggtg 51360 aatgggtggg ctgtgttcag agagcagccg cagcggattc ctagagcatg gctgaagaag 51420 tgggcaggct atgagagccc actcacagct gaagcccccc tcgtgcccag tgggaataag 51480 gacagcactc tgccccctgg gactggtccc ttggcggtag tgagctccct ggcactggtg 51540 tgtgcaagca caaactgtgc catcccattt accctcctgt cacttgagta atcactcttg 51600 gcctgacccg ctgctaggag caaggatata aaggagactc agatctgtcc tcaccccagg 51660 gcggggacag gataggcaag ccctctggtc cagggcagag gaaggaagta gtgaaggaag 51720 gcaggcctgg cctggaagcc ggggtggagt gaattatgct gggcaccaga aagactacac 51780 ggaggaggag gctgagcact gggctttgga gaggtgggca tggaggggcc agggaggttt 51840 gtaagcatca gcacctggga accttcgtca ctaccgccat cggacttgaa gggtcgtcat 51900 tcacagctga atcctgcggg aggagaggga gggctttgga ttcatggggc ttccagttct 51960 ctttctgcct cttttagagc tttgaggaaa tctctctcca tctccaggcc ccagttttct 52020 cacctgagaa tcagggataa taagaataat gcccccggtg tggagctgtt gtgtggattt 52080 attaagataa tgcctgagct ggggcctcgc tggcagcaat tgccgttatt tatggtagtg 52140 aggctggcaa ccccgcccag cctcaacgct cacctctgtg tgagggcttg ggggtgggct 52200 gggattctca cacggggcca gccacacagg acccatccat gcactgacag tcagttccac 52260 ggggcagaga aggaggaggg ctgcacacac cacaggcatt ccaggaggac ttcctggagg 52320 acgcagtctg caatccctca agctctggga gcacttccca gggataaggc ctgggcatcg 52380 cccacaggct acagggcaag acaggggcag aactcaggga gcctgactcc caggtgtggg 52440 ttcccctttt ccatgaggac acctctcata atagagtgtg ccaaatgctg ggggaccatg 52500 gggcggtgtg tgctgggctc acagcacctc ttggagaggg ccaaagtact gtttctcata 52560 gtgccctgcc aggcctggcc agggcctcca agtgagccca gtctgtcctg ggctcatggg 52620 cggcatctca cagacccagc tgctgcagtt ggatgctctt cagacctcag tgtggggccc 52680 acttgaagtg ctggagacac aggggtgcaa gaggcgtgtg tggggcctca ggcccttccc 52740 tagagatgct ggtcatggcc tcaagccacc caagagattt ggcagccatg atttcctccc 52800 ctcctcgggg gccgggggtg aggcctgttt ggaccgcagt gggaaaaggg tgcagagggg 52860 cagccccctc ttcccacctg cttcatctca ggactttatc acttgggagt ggggacaaga 52920 catgtttaca tggccctgca tttgtttccc attattcatc agcactggcg agtcattgtt 52980 ccctagtaga gtaaacagcc ctgtcccaag gcccagccgc cctgccaggt cactgagggt 53040 ttgtagatgc cttacgtcaa ccgccctttg cttcaagctt tcagtgaggt gaggagtggc 53100 caggccagat ggctgcagat gggcggcgcc agggagcttc ctcgtgacag ggatgaggta 53160 gcatttctgc actgggaact cagcatttga gagtctgtgt ctgtttggtt tgctttacag 53220 tcggaccttt aatagggctg gggaagccaa ggcgcagagc agggaatctg agaaccatga 53280 gaaggaaggt aacaaccgtg acatgagagg ggtccgaact gagtcccagg gacagctgcc 53340 catgtccagg tcccattgtt aagtgtatgc cagcacagtt ctctacaggg tcttataggc 53400 ccagagatgg gactaacccc aggaatgctg ggtccttccc gatgctcctc acggcaagct 53460 gcatctgggg ctgacgtgca tgtgctcaag ttgacactgg actccagctc gtgtgaggag 53520 cagccggctc ttcgcagcat tggtctgagc acatgcgctg acgcagccag cttagcctgg 53580 ggccaaaggc gcgtgttctg cagccagacc gcagggctgg gtcccgcctt cactctggtg 53640 tgctgtgtca ctctactcaa gctactccag ctcccggagc ctccgtgtcc tcatctgtaa 53700 aatggggtca ataacatgac ctgtcaccca ggtagctgtg aggatcgcgt gggcctgcgc 53760 ctaacacata ataaacactc acagatgttt gctttgtgtt gttagcagga tgagtaggac 53820 acggggcctg gcttggtgct tttcatggtc cagtgcaggc tggagacaga ccccaggggc 53880 agacatggct gaggcttgga ggggagggag gcgaccactc gccaccccta ggggctgcgc 53940 ccagcaaagg tggcatgggc actgggcccc tagggggtcc taagcaaggc tttgttgaat 54000 ggagaaaggt gctgaggata gtccctctcc ctcctcccca ggcttcccca gtcagaatgg 54060 tgcgatcacc tggctcctct cagcgagggc cacttctacc attttagctg taaccactgg 54120 cggcttttag agttcagagc tctgcctgcc tcctctgact gcccacacgg ctgacatttg 54180 agcttgccaa agaataatgg cctcgctgtc ggcctcaaag gcagccgtgt ggtgtcttag 54240 gtggtaaagt ggtctgtcgt ccatgagtct aaataggacc tggctcaaat cgctccacag 54300 ccaagtcctc tcccagttca gtgcaggtca ccaactcttt accttttcac atccttttgg 54360 ttccaatagt aaaagatgtc tatgttaaaa agaagtgtat caaaagctca acaccgaaga 54420 gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt gtgtgttagg gaccggggat 54480 tggctagaag cagccagtag ctcacgccgc ctttgtggtt ttatatattt gcctattaaa 54540 atgacaatac agacatggaa cattaaggtt taagaagccc ttctttcatt aaacaaactg 54600 acagagcagg gggttatgac tctggtaatt gaaacacgct gttgtgctca agaccagaac 54660 tccataaaga ctgttttcag ccaatagcgc cctttgtgcc agcggcctct ggtcagaaat 54720 gagtgtcggc cctgaggtct gcctctcccc gagagtggga aagaccactt ggcagccttc 54780 cacagccatc ttggcagccg gaggtcaggg ccttttctta ataaaaacct cctcattctc 54840 ggagtttttg aaatcagttg cagggcacag agccttgggg cactgtgctg tgctccagcc 54900 tgttatcgtg ttgtgctgct gatggtaaac ctgagctgag tcaagagacg gggctcgtgg 54960 ggttgcagct ggcaaagctc catgtgttgg ggacagctgc tgcaggctgc tgtgtcttcc 55020 tagagtgggg ggtctggcga cgtcactgag agctgaggtt tcagggtcag accaccgggt 55080 ttgaatcctg cctctgccac ttaccatacg taggacttta gacaagtgac tttgcccctc 55140 cgcacctaag tttcctcatc tataaaatgg actggtacct ggatctgact tacagggttg 55200 ctgtgagaat taaaggaatt aatacaggta agatgcttag aacagtgctg ggcactcaga 55260 cagcactgtt gagttggagt gagctagcat catagccact ggactctttc caggacttgc 55320 tctcgggagt accaccgtgc agcatcacca tggagtcccg ctgtaccagt atagcacagc 55380 acgatggagg cccaccatgc cactgtagcg cagcgccatg ggagcccacc gtaccactgt 55440 agcgcagcgc gatgggggcc caccgtgcca ctgtagcaca gcctgatggg ggcccactgt 55500 accactgtag cacagcacaa tggagaccca ctgtaccact gtaccactgt accactgtag 55560 cacagcgcga tggagaccct ccgtaccact atagcacaga gcgatggagg cccactgtac 55620 cactatggca cagcacaatg gaggcccact gtagagtgcc accatggtgc agggccgtgg 55680 aggcccactg tacagtatca ccatcacaca gcaccaggga ggccctctct ggagtccctc 55740 ccttcagggc catgtgagga aattcactgc atccctgtcc cgccagcccc tcatgccctg 55800 cttccaactt aggtgtgatc tctggtcccc ttctcttcct tttctcacag atgtggacga 55860 gtgtcaggac aataatggtg gctgccagca gatctgcgtc aatgccatgg gcagctacga 55920 gtgtcagtgc cacagtggct tcttccttag tgacaaccag catacctgca tccaccgctc 55980 caatggtgag tacagcctat gctgaccagg catgtccccc cccaggatgg gcagccccca 56040 gagtcccctt ctccacatct caattctggg gccctcaagg tcaaggcagg gaattttggt 56100 ggtagtctga atgactgttt tgcacgtctg gtattggttc tgcatgggcc tccttccagt 56160 tccttccctc tacctgctac actagggctg cgggtgtttc tcgtgtttat atgtggggcc 56220 gcaagtagca catgtgacca gaggagctgt tttcctttct gagttggggg ctggctgtgg 56280 ccaggaagag tggggcccca ttctccatgg gctccttctc caaagggggc ttgaggctat 56340 ccaggctgtg tgccaacttc tctgtctcca tgagcctggc agcaccagcg actccctgct 56400 gcatgttcat tgggtttccc gccaggagag ggtccttgtg gtcgggcgcc tgctgtttgg 56460 aagccaggca gtgtggcagg ccagcctggg gaggtgcaga gggccccagg aagacacccc 56520 accagctgga gcactaggtg gcagacccag gctgaagtgg agcctggcca ccagccaagc 56580 ccagcaggca aaggaacttg gtgttacggc atcagtggtc agatcctgga gtttcggctc 56640 agggcagcag agctgtgagg tggcggcaga gctgtccaga aagccaggac acatgtgctt 56700 ggaggagaga gccaggacac atgtgcttgg aggagagagc caggacacat gtgcttggag 56760 gagagggcca ggacacatgt gcttggagga gagagccagg acacatgtgc ttggaggaga 56820 ggggcttcca ggcagagaac agcttttgcg gaggcacatc tcttgcttaa gataatgcaa 56880 gggcaggcat ctgaggcagg gctgtgtacc aaagcagagt gtgctgtgag ggcagggcag 56940 gagccaaggt tcccagggcc tggctgtcgt gagctgtcaa gggaataaat gtaaggaaga 57000 aggccagaac tgccccagtt caggcacgcc cccattgctg acccttaaca aggaggaggc 57060 gctggaggct tgcgggcata gagggcgttc ctgggaaggt cgcccctctc tggtacacag 57120 cacctgcaga aggctcagag aggggctcac gctgagagat ggggaaccaa agggcacgca 57180 ctgggctcca ggccagccgg accctgtgtg aatccagctc ctcctctccc acgctggaag 57240 ccttcccatg ggcggctcta ctgactgctc cccagattcc tcgcctgcaa aatggggaag 57300 tggtgttacc cggcagggcg ttcagagatg gagcaggacc gtgggatgag gttccagcct 57360 cccgtgagca ggcaggaggt tgtgaggtgt gagtctgcca gcccaggcat gagtttcatt 57420 agaaaacagt tcctgagaaa gtgaaagcaa aaacatttaa aaagtactca ggataataaa 57480 gtggaaatac tcgaacaggc tccttagaat tcttagtgtt tgttgcctca aaggcaggac 57540 gggcctgcta atcatggctc tgtggtgtcc ccagaagaac agaaagcccg agctccgtgg 57600 ctcctggcac ttgctgctgt cacattgtcc acactccacc caggtggctc ccgggcatca 57660 ggagtttgtt ttgcgccttg taagacctcc cagttgtggg ctgtggggcc aagctgccca 57720 cgatggaggc aaaccctata aaccaggact ctgagcccaa caggttgtat aagaagcaga 57780 ttgatgggga cagagtgagc aagtgcgggg aggggcctct gctttcatcc agggagggga 57840 gttcacagag tgactgctct gagcaggctg taaagtcgca ggccagggtg gcgtgagcct 57900 ccttttcagc caggctgtgt gtgctctgtt cctttgaagc ccggctttct ccccagcagg 57960 actccaggta gagctgaggc ccctggttga aagaagggtg tgctgtgggc agatcacacc 58020 cgcagccaca gcctgtttgt tacaggtttg gcctgtaagc atctgctgtg ctgaggaggt 58080 tacaaacctt agcgtcccct acaggactgg ggttggggag gggatgacgt gggagcagcg 58140 acagcagggg ctgctggggc cacacgctta ctctgagcca ggcacgggcc tgagcactgc 58200 ccagagacaa gctcactcca cctttgccac tgcccggcga ggctgggttg tgacgctgag 58260 gaaggcgaag cccagcgaag ttagggaaga ggcagagcca ggatctgagc caggcacgct 58320 agctatgggg cccgctcctt gggaggtgat gcggtgtgag aggaaagaaa cgggtggtgc 58380 agcagacggt gctggagctg atgagaaagc caggtgggaa gcttgtgggg aatgtgccag 58440 gctgggcgcg tgcaaaggcc ctggggtggg aatgggcacg tgaaaagctg aacaaagggt 58500 gggacgaagg agcagagagc acgaagcggg aggagcccga ggcggggagg tgggggctgg 58560 acaacatggg gcctggtggg ctgtggcaag agtttggatt ttgggtggag ggcagctgtg 58620 ggaaagctgg ttgagcagag gtaggaagtg atgcttaggg gagaggggag gccatctggg 58680 agaacgccag cacttccagg ggctggcatc tcataaattg tgcagtggct ggtgttgggt 58740 gggaccctgg gcacacatgg ctcactccac ccagatgccc caggtggtca gatcctgatt 58800 tttcaggaag ccaggagtcc agctttaacc agaatatgga tttgggggcc tcagtcccaa 58860 tctgcattaa ccagcgtgtc ggttaaagaa gtgccttctc tccttacgat ttttgtgtgg 58920 cctctcctga ttttttgatc tgggcaatga aatcagtcca aaaaacaaca gataacttat 58980 cagat 58985 4 74 PRT Human 4 Met Gly Ala Ala Ala Val Arg Trp His Leu Cys Val Leu Leu Ala Leu 1 5 10 15 Gly Thr Arg Gly Arg Leu Ala Gly Gly Ser Gly Leu Pro Gly Ser Val 20 25 30 Asp Val Asp Glu Cys Ser Glu Gly Thr Asp Asp Cys His Ile Asp Ala 35 40 45 Ile Cys Gln Asn Thr Pro Lys Ser Tyr Lys Cys Leu Cys Lys Pro Gly 50 55 60 Tyr Lys Gly Glu Gly Lys Gln Cys Glu Asp 65 70 5 74 PRT Mus musculus 5 Met Gly Ala Ala Ala Val Arg Trp His Leu Ser Leu Leu Leu Ala Leu 1 5 10 15 Gly Ala Arg Gly Gln Leu Val Gly Gly Ser Gly Leu Pro Gly Ala Val 20 25 30 Asp Val Asp Glu Cys Ser Glu Gly Thr Asp Asp Cys His Ile Asp Ala 35 40 45 Ile Cys Gln Asn Thr Pro Lys Ser Tyr Lys Cys Leu Cys Lys Pro Gly 50 55 60 Tyr Lys Gly Glu Gly Arg Gln Cys Glu Asp 65 70 

That which is claimed is:
 1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of: (a) an amino acid sequence shown in SEQ ID NO:2; (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
 2. An isolated peptide comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence shown in SEQ ID NO:2; (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
 3. An isolated antibody that selectively binds to a peptide of claim
 2. 4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2; (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).
 5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2; (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).
 6. A gene chip comprising a nucleic acid molecule of claim
 5. 7. A transgenic non-human animal comprising a nucleic acid molecule of claim
 5. 8. A nucleic acid vector comprising a nucleic acid molecule of claim
 5. 9. A host cell containing the vector of claim
 8. 10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
 11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
 12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
 13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
 14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
 15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.
 16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.
 17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.
 18. A method for treating a disease or condition mediated by a human secreted protein, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim
 16. 19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.
 20. An isolated human secreted peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.
 21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.
 22. An isolated nucleic acid molecule encoding a human secreted peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or
 3. 23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or
 3. 